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INTRODUCTION
This short version complies with the intention 
expressed in the introduction to the full text 
Italian Guidelines for the use of antiretroviral 
drugs and the diagnostic-clinical management 
of people with HIV-1 infection. By definition, 
this version should not be considered complete-
ly exhaustive with respect to the full text ver-
sion of the Guidelines (HIV/AIDS Italian Expert 
Panel, 2014).
This publication highlights only the main up-
dates of the 2014 Guidelines version in respect 
to the 2012 edition (Antinori, et al. 2012), that 
is: when and what to start combined antiretro-
viral therapy (cART), treatment optimization, 
retention in care, the use of new anti HCV drugs 
for the therapeutical management of HIV/HCV 
infected patients. Recommendations in these 
guidelines are based upon scientific evidence 
and expert opinion (Table 1).
It was decided to give not to discuss in toto cer-
tain fundamental parts of the extended versions 
such as comorbidities management, the popula-
tions requiring special attention (elderly, women, 
immigrants, children), the conditions requiring 
special attention (drug and/or alcohol addiction, 
detention) or the situations requiring special at-
tention (transplants). For all these populations, 
conditions or situations, it should be referred at 
the full text version of the Guidelines (HIV/AIDS 
Italian Expert Panel, 2014 #604).
Lastly, it was decided to refer the reader to the 
extended version for all bibliographic citations, 
except for the references cited at the end of this 
version concerning the 2014 updates.
TABLE 1 - Rating scheme for degree of 
recommendation (a) and level of evidence (b).
a) Degree of recommendation
A Highly recommended
B Moderately recommended
C Optional
b) Level of evidence
Level I The data are obtained from at least 
one controlled, randomized study with 
sufficient power or from a meta-analysis 
of controlled studies
Level II The data are collated from non-
randomized studies or from cohort 
observational studies
Level III Recommendation based on case reviews 
or agreement among experts
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WHEN TO START
Antiretroviral therapy is recommended in all 
the subjects with chronic HIV infection who 
are willing to start therapy, regardless of their 
CD4 T cell count or viral load. 
In particular, considering the evidences and the 
strength of the clinical studies:
• cART is strongly recommended in all the in-
dividuals with a CD4 T cell count below 500 
cells/µl. Rating of recommendation is [AII] 
in patients with CD4 T cells count between 
350 and 500 cells/µl and [AI] for the individ-
uals with a CD4 T cell count lower than 350 
cells/µl. 
• cART is moderately recommended [BIII] in 
patients with a CD4 T cell count above 500 
cells/µl. The rate of recommendation for 
these subjects can switch to [AII], highly rec-
ommended, if a decrease in CD4 T cell count 
of more than 100 cells/µl/year is observed or 
if the levels of plasma HIV RNA are higher 
than 20.000 copies/ml. 
Adequate counselling should be given to pa-
tients starting cART with a high CD4 T cell 
count (>500 cells/µl). Patients need to be aware 
of the potential benefits of early therapy start 
(decrease of viral replication and chronic in-
flammation, better immunological recovery, 
reduced risk of AIDS related and not AIDS re-
lated morbidity, reduced risk of transmission) 
as well as of the risks associated with long term 
therapy (potential drug toxicities, risks related 
to incomplete adherence). 
Healthcare workers should highlight the im-
portance of a complete adherence to cART, 
particularly in patients with a CD4 T cell count 
within the standard range for healthy popula-
tion who start therapy in an early phase of in-
fection. 
Moreover, antiretroviral treatment is recom-
mended in the following groups of patients in 
order to prevent HIV transmission:
• Patients who have HIV negative sexual part-
ners, regardless of their CD4 T cell count or 
viral load [AI].
• HIV positive individuals requesting treat-
ment, regardless of the reason [AIII].
If offered to the patients, treatment as preven-
tion must be discussed in a dedicated meeting 
where the health care specialist will provide 
extensive information and discuss therapeutic 
options with the patient. Since the effective-
ness of treatment as prevention strongly relies 
on the willingness and ability of patients to ad-
here to antiretroviral treatment, the patient’s 
decision of starting therapy must be taken in 
absence of any psychological pressure and 
only after an adequate counselling. Providing 
sufficient information to understand all the 
advantages and disadvantage of early antiret-
roviral therapy start as well as the necessary 
time frame to process the information and 
take a considered decision must be intended 
as a standard of care to be pursued in all HIV 
infected patients, regardless of their CD4 T cell 
counts [AIII]. 
Finally, antiretroviral therapy is recommended 
in patients with primary HIV infection (PHI). 
This group of patients includes individuals pre-
senting symptoms consistent with an acute ret-
roviral syndrome (acute patients) and individ-
uals diagnosed within 6 months from the pos-
sible transmission events (recent infections). 
Providing antiretroviral treatment during PHI 
represents a unique intervention opportunity 
TABLE 2 - Recommendations for Initiation of cART in patients with PHI.
Clinical condition CD4 T 
lymphocyte 
count
Recommendation 
for treatment
Strength 
evidence
Related literature
Asymptomatic 
patients with acute 
or recent infection
Any value Moderately 
recommended
[BII] (Schacker et al. 1996; Kahn and 
Walker 1998; Oxenius et al. 2000; 
Rosenberg et al. 2000; Fidler et al. 
2002; Pilcher et al. 2004; Mehandru 
et al. 2006; Brenner et al. 2007; 
Daar et al. 2008; Lockman and 
Creek 2009; Ananworanich et al. 2012; 
Grijsen et al. 2012; Le et al. 2013; 
Saez-Cirion et al. 2013)
Symptomatic patient 
with acute or recent 
infection
Any value Highly 
recommended
[AII]
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TABLE 3 - Recommendations for initiation of cART in patients with chronic infection.
Clinical 
condition
CD4 T 
lymphocyte  
count
Recommendation 
for treatment
Strength 
evidence
Related literature
Asymptomatic <350 
cells/μl
Highly 
recommended
[AI] (Badri et al. 2004; Moh et al. 2007; 
Wong et al. 2007; Strategies for 
Management of Antiretroviral 
Therapy Study et al. 2008; When To 
Start et al. 2009; Severe et al. 2010)
350-500 
cells/μl
Highly 
recommended
[AI] (Cozzi Lepri et al. 2001; Mocroft 
et al. 2007; Strategies for 
Management of Antiretroviral 
Therapy Study et al. 2008; When 
To Start et al. 2009; Collaboration 
et al. 2010; Severe et al. 2010; 
Cohen et al. 2011b; Collaboration 
et al. 2011; Plettenberg et al. 2011; 
Collaboration of Observational et 
al. 2012; Hogan et al. 2012; Lucero 
et al. 2013; Grinsztejn et al. 2014) 
500 
cells/μl
Moderately 
recommended
Particularly 
recommended if one 
or both the following 
conditions are observed:
- CD4 T cell decrease 
>100 cells/µl/year;
- HIV-RNA >20.000 
copies/ml
[BIII]
[AII]
[AII]
(Hogan et al. 2012; Lucero et 
al. 2013; Grinsztejn et al. 2014; 
Montaner et al. 2014; Nolan and 
Wood 2014) [30-34]
AIDS Any 
value
Highly recommended [AI] (Badri et al. 2004; Moh et al. 2007; 
Wong et al. 2007; Strategies for 
Management of Antiretroviral 
Therapy Study et al. 2008; When 
To Start et al. 2009; Severe et al. 
2010)
Pregnancy Any 
value
Highly recommended [AI] (Hoffman et al. 2010; Tubiana et 
al. 2010)
HIV-associated 
nephropathy (HIVAN)
Any 
value
Highly recommended [AII] (Schwartz et al. 2005; Estrella et 
al. 2006; Lichtenstein et al. 2008)
Non-AIDS defining 
cancers
Any 
value
Highly recommended [AII] 
HIV-associated 
Neurocognitive 
Disorders (HAND)
Any 
value
Highly recommended 
for HIV-Associated 
Dementia (HAD) or Mild 
Neurocognitive Disorder 
(MND)
[AII] (Mellgren et al. 2005; Robertson et 
al. 2007; Cysique et al. 2009)
Chronic HBV infection 
requiring treatment
Any 
value
Highly recommended. 
In cases in which 
there is indication 
for HBV treatment 
nucleoside analogues are 
recommended.
[AII] (Thio et al. 2002, Peters et al. 2006; 
Matthews et al. 2008)
Treatment as 
prevention: 
serodiscordant couples 
and other conditions
Any 
value
Always in case of highly 
motivated patients 
- Serodiscordant couples: [AI]
- Multiple unprotected sexual 
intercourse; presence of other 
sexually transmitted diseases 
[AII]
(Attia et al. 2009; Donnell et al. 
2010; Reynolds et al. 2011)
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during the clinical course of the disease (Me-
handru et al. 2006) and it is of particular rel-
evance for the spreading of the disease since 
subjects during PHI have the highest likelihood 
to transmit the infection. The rate of recom-
mendation for treatment of acute and recent 
infections depends on the presence [AII] or ab-
sence [BII] of symptoms. 
Recommendations (including rates of recom-
mendation, levels of evidence and relevant lit-
erature) concerning the opportunity to treat 
in different clinical conditions in patients with 
acute or chronic infection are listed in Table 2 
and Table 3. It is worth to note that treatment 
is always recommended [AI] in presence of op-
portunistic infections, although the timing for 
initiation of therapy can differ in relation to the 
specific characteristics of the ongoing opportu-
nistic disease [for a more detailed review of this 
issue we refer the reader to the complete ver-
sion of the Italian Guidelines (HIV/AIDS Italian 
Expert Panel 2014)]. 
THERAPEUTIC REGIMENS
The goal of starting cART in HIV positive pa-
tients is the reduction of HIV related mortality 
and morbidity and the consequent improve-
ment of patient’s quality of life. Achievement of 
a complete virological suppression (decrease of 
plasma HIV RNA levels below the limit of de-
tection of standard diagnostic tests) within 3-6 
months from the start of cART is necessary to 
reach this goal. 
Moreover, suppression of viral replication is 
also associated to immunological recovery and 
reduction of the inflammatory state and of its 
associated complications. Because of their rele-
vance to public health, also the indirect effects 
potentially associated with suppression of vi-
ral replication such as a reduced risk of HIV 
transmission and the resulting contraction of 
HIV epidemics as well as the positive effects in 
term of HIV de-stigmatization must be actively 
pursued. 
The recommended pharmacological treatment 
for HIV patients naïve to therapy is usually 
made of a combination of different antiretrovi-
ral drugs, called therapeutic regimen. In this re-
gard, clinical trials, which provide fundamental 
information for the choice of therapy, are usu-
ally based on comparison of different regimens 
rather than single drugs. Nevertheless, for the 
choice of an appropriate drug combination is 
mandatory to consider also the information 
concerning the properties of the single mole-
cules included in the therapy. 
The critical factor determining the efficacy of a 
pharmacological treatment lies in its capacity 
to meet patient’s clinical and non-clinical needs. 
Table 4 provides a list of the factors that play a 
role in determining the efficacy of a therapy and 
therefore need to be considered in order to iden-
tify the best first regimen for a given patient.
Given the fact that current cART needs to be 
taken lifelong, it seems appropriate to imple-
ment the first regimen according to a stepwise 
strategy, in which a therapeutic combination 
providing a strong and rapid reduction of vi-
ral load (in order to achieve the goals resulting 
from reduction of viral replication), is followed 
by an optimized regimen, tailored to maintain 
viral suppression while better matching the 
present and future needs of the patient (see 
chapter 3, Treatment Optimization).
TABLE 4 - Factors influencing the choice of the first 
regimen.
Category Factors
Drugs and drug 
combinations
Virological efficacy.
Immunological efficiency.
Compactness/convenience.
Toxicity and tolerability.
Potential drug-drug interaction.
Genetic barrier.
Extensive clinical use.
Clinical practice 
or diagnosis
Presence of an AIDS defining 
conditions or other associated 
pathologies.
Plasma HIV RNA levels.
Presence of transmitted 
resistances.
HLA type (presence or absence of 
HLA-B*5701).
Non-clinical Assessment of patient’s 
willingness and readiness to start 
treatment.
Population specific 
characteristics.
Particular conditions.
For a more detailed description of the single factors influencing the 
choice of the first regimen we refer the reader to the last edition 
of the Italian guidelines for the treatment of HIV infected patients 
(HIV/AIDS Italian Expert Panel, 2014).
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In agreement with the recommendations for the 
treatment of acute and recent infections, phar-
macological treatment of HIV patients at these 
stages of infection needs to include one of the 
regimens recommended for subject with high 
viral load (HIV RNA >100,000 copies/ml) [AII]. 
Despite the lack of evidences deriving from clin-
ical trials, in patients characterized by extreme-
ly high viral loads (HIV RNA >500,000 copies/
ml), infection diseases specialists might favour 
regimens including integrase inhibitors, which 
are characterized by a stronger and faster ac-
tivity [CII] compared to other classes of drugs. 
Moreover, clinicians might consider the use of a 
combination of four drugs instead of three, se-
lecting the molecules that guarantee the fastest 
virological suppression [CIII].
Classification and degree of recommendation 
of cART regimens. 
Recommended regimes (Table 5a) [A] - Regi-
mens meeting all the following criteria: 
• Proven efficacy in controlled, randomized 
clinical trials with sufficient potency (quali-
ty of the study, size and characteristics of the 
control group);
TABLE 5A - Antiretroviral regimens recommended for starting cART.
Regimen Degree of recommendation/
Level of evidence
Related literature
TDF/FTC+EFV [AI] (DeJesus et al. 2004; van Leth et al. 2004; Gallant et al. 
2006; Arribas et al. 2008; Riddler et al. 2008; Lennox 
et al. 2009; Sax et al. 2009; Post et al. 2010; Daar et al. 
2011; Molina et al. 2011; Sax et al. 2011; Sax et al. 2012; 
Cohen et al. 2013b; Rockstroh et al. 2013; Walmsley et al. 
2013; Carey 2014; Cohen et al. 2014; Wohl et al. 2014)
ABC/3TC+EFV 
(recommended if HIV-
RNA <100000 copies/ml)
[AI] (Sax et al. 2009; Post et al. 2010; Daar et al. 2011; 
Sax et al. 2011)
TDF/FTC/RPV 
(useable only if HIV-RNA 
<100000 copies/ml)
[AI] (Molina et al. 2011; Cohen et al. 2012; Cohen et al. 2013a)
TDF/FTC+ATV/r [AI] (Ortiz et al. 2008; Lennox et al. 2009; Molina et al. 2010; 
Daar et al. 2011; Eron et al. 2011; Soriano et al. 2011; 
Sax et al. 2012; Orkin et al. 2013; Rockstroh et al. 2013; 
Clumeck et al. 2014; Landovitz et al. 2014)
ABC/3TC+ATV/r 
(recommended only 
if HIV-RNA <100000 
copies/ml)
[AI] (Sax et al. 2009; Daar et al. 2011; Sax et al. 2011)
TDF/FTC+DRV/r [AI] (Ortiz et al. 2008; Orkin et al. 2013; Clotet et al. 2014; 
Landovitz et al. 2014)
ABC/3TC+DRV/r [AII] (Clotet et al. 2014)
TDF/FTC+RAL [AI] (Lennox et al. 2009; Raffi et al. 2013a; Raffi et al. 2013b; 
Rockstroh et al. 2013; Landovitz et al. 2014)
ABC/3TC+RAL [AII] (Raffi et al. 2013a; Raffi et al. 2013b)
TDF/FTC/EVG/COBI [AI] (DeJesus et al. 2012; Sax et al. 2012; Clumeck et al. 2014; 
Wohl et al. 2014)
TDF/FTC+DTG [AI] (Raffi et al. 2013a; Raffi et al. 2013b; Clotet et al. 2014)
ABC/3TC+DTG [AI] (Raffi et al. 2013a; Raffi et al. 2013b; Walmsley et al. 2013; 
Clotet et al. 2014)
NNRTI based regimens are not recommended in presence of mutations conferring resistance to NRTI and NNRTI.
Due to the occurrence of hypersensitivity reactions (HSR), ABC is not recommended in subjects harbouring the HLA allele B*5701.
The approved dosage of DRV/r is 600/100 mg once a day.
EVG/COBI is contraindicated in patients with impaired renal function (GFR ml/min/1.73m2). Information on kidney toxicity of this combi-
nation is limited. The standard dosage of EFV is 600 mg/once a day. The off label dosage of 400mg twice daily proved to be not inferior to 
standard dosage if prescribed in association with TDF/FTC.
“/” = co-formulated; “+” = not co-formulated.
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• Favourable acceptability, tolerability, and 
safety profiles;
• Well established use in clinical practice 
based on the number and extent of clinical 
studies, on the data deriving from observa-
tional studies, or on the extensive clinical 
use after the launch on the market.
Alternative regimens (Table 5b) [B] - Partially 
meeting the criteria for recommendation be-
cause of the following reasons:
• Regimen efficacy is supported by incom-
plete evidences;
• Suboptimal acceptability, tolerability, and 
safety profiles;
• Supported only by a limited amount of clin-
ical data and lacking extensive clinical use 
in real life. 
Alternative regimens are suggested in cases 
where the patient does not tolerate or is unable 
to take recommended drugs (due to resistance, 
toxicity or intolerance).
Optional regimens (Table 5b) [C] - Regimens 
showing:
• Insufficient or evidences supporting regi-
men efficacy;
• Suboptimal acceptability, tolerability, and 
safety profiles.
Optional regimens are suggested in cases where 
TABLE 5B - Alternative and optional drugs combinations for first regimens.
Regimen Degree of 
recommendation/Level 
of evidence
Related literature
Alternative TDF/FTC+LPV/r [BI] (Ortiz et al. 2008; 
Riddler et al. 2008; 
Smith et al. 2009; 
Molina et al. 2010; 
Orkin et al. 2013)
ABC/3TC+LPV/r [BI] (Smith et al. 2009)
TDF/FTC+NVP [BI] (van Leth et al. 2004; 
Soriano et al. 2011; 
Cain et al. 2012)
DRV/r + RAL 
(only if CD4 T cell count >200 cells/µl; 
caution must be used when prescribing 
this combination in patients with HIV 
RNA viral load >100.000 copies/ml)
[BI] (Raffi et al. 2014)
LPV/r + 3TC [BI] (Cahn et al. 2014)
TDF/FTC+ATV/COBI [BI] (European Medicines 
Agency 2013; 
Gallant et al. 2013)
ABC/3TC+ATV/COBI [BIII] (Gallant et al. 2013)
TDF/FTC+DRV/COBI [BIII] (Gallant et al. 2013)
ABC/3TC+DRV/COBI [BIII] (Gallant et al. 2013)
Optional TDF+3TC+EFV [CI] (Gallant et al. 2004)
ABC/3TC+RPV
(only if HIV-RNA <100.000 copies/ml)
[CII] (Cohen et al. 2011a; 
Cohen et al. 2013c; 
Nelson et al. 2013; 
Molina et al. 2014b)
LPV/r + RAL [CI] (Reynes et al. 2013)
LPV/r + MVC [CI] (Nozza et al. 2014)
NNRTI based regimens are not recommended in presence of mutations conferring resistance to NRTI and NNRTI.
Due to the high risk of developing HSR, ABC is not recommended in subject harbouring the HLA allele B*5701.
The approved dosage of DRV/r is 600/100 mg once daily.
EVG/COBI is contraindicated in patients with impaired renal function (GFR ml/min/1.73 m2). Information on kidney toxicity of this combi-
nation is limited.
NVP is not recommended for use in women with a CD4 T cell count >250 cells/µl or men with a CD4 T cell count >400 cells/µl. NVP is initiated 
at half its usual dose (400 mg/day) in the first 14 days of treatment using extended-release tablets.
 “/” = co-formulated; “+” = not co-formulated;
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the patient does not tolerate or is unable to take 
recommended or alternative regimens (due to 
resistance, toxicity or intolerance).
Table 6 reports the degree of recommendation 
and level of evidence as well as pro and cons 
of single drugs and drug combinations taking 
in account information concerning tolerabil-
ity and toxicity, pharmacological interactions, 
formulations, posology and costs deriving from 
randomized clinical trials.
TREATMENT OPTIMIZATION
Therapy simplification: This treatment 
scheme, also known as Less Drug Regimen 
(LDR), refers to an induction-maintenance 
strategy and is intended to reduce the number 
of antiretroviral drugs included in a given reg-
imen. Once plasma viral load is not detectable 
anymore and immunoreconstituition is taking 
place (at least 6 months after achieving viral 
suppression), the aim of switching to a LDR 
is to maintain viral control while at the same 
time limiting or avoiding long term toxicities, 
increasing tolerability and reducing pharmaco-
logical interactions. Such approach is of partic-
ular interest in light of the increasing rates of 
comorbidities and of the more widespread use 
of non-antiretroviral medications related to the 
aging of the HIV population.
The following paragraphs describe the current 
therapeutic scenario for switching to LDR in 
cART treated patients with viremia below the 
detection limit. To give a broaden overview of 
all the possible therapeutic strategies, drug 
combinations are described regardless of the 
specific indications provided in the technical 
datasheets. 
Dual therapy (Table 7). Initially, dual therapy 
regimens were developed with the aim of ex-
cluding nucleoside reverse transcriptase inhib-
itors (NRTIs) from the therapeutic combina-
tions, since these drugs show higher long-term 
toxicities. Recently, combinations including 
a ritonavir boosted protease inhibitors (PI/r) 
in combination with lamivudine (3TC) and/or 
emitricitabine (FTC) have been evaluated, giv-
en that the toxicities associated with the use of 
these NRTIs are significantly lower or absent 
TABLE 6 - Summary of rationale/advantages/disadvantages of first line regimens.
ARVs class Drug(s) Evidences of efficacy deriving from RCT Advantages Disadvantages
N(t)RTI 
(2 drugs 
backbone)
ABC/
3TC
- Evaluated in comparison studies against TDF/FTC 
in association with EFV, ATV/r, DTG.
- Inferior to TDF/FTC if used in association with 
ATV/r e EFV in patients with basal HIV RNA viral 
load ≥100,000 copies/ml (Sax et al. 2009; Post et al. 
2010; Sax et al. 2011).
- Comparable efficacy to TDF/FTC, if used in asso-
ciation to RAL e DRV/r demonstrated only in sub-
group analysis of RCT (Raffi et al. 2013a; Raffi et 
al. 2013b; Clotet et al. 2014).
- Limited information concerning its association 
with RPV (Cohen et al. 2012).
- Superior to TDF/FTC (in association with EFV) 
if used in association with DTG (Walmsley et al. 
2013).
- Once a day regimen
- Available in co-formula-
tion with DTG.
- No food-drug interac-
tions reported.
- No evidences of neph-
rotoxicities (Post et al. 
2010; Daar et al. 2011).
- Generic, not-co-formu-
lated, forms of ABC e 
3TC are available (higher 
pill burden/day).
- Due to the high risk of developing HSR, ABC is 
not recommended in subjects harbouring the HLA 
allele B*5701.
- The use of ABC has been associated with an in-
creased risk of cardiovascular disease in observa-
tional studies. RCT and meta-analysis did not con-
firm these observations (Group et al. 2008; Ding et 
al. 2012).
TDF/
FTC
- Used as standard NRTI backbone with all recom-
mended regimens.
- Only one recommended NRTI backbone in asso-
ciation with RPV and EVG/COBI.
- Superior to ABC/3TC in association with EFV 
and ATV/r in patients with baseline HIV viremia 
>100,000 copies/ml(Sax et al. 2009; Post et al. 2010; 
Sax et al. 2011).
- Once a day regimen 
- Available in co-formula-
tion and single tablet for-
mulation with EFV, RPV, 
EVG/COBI.
- No food-drug interac-
tions reported.
- Activity against HBV. 
Preferred over 3TC alone 
in HBV/HIV co-infected 
patients.
- Use of TDF/FTC has been associated with an 
higher risk of kidney failure and renal tubular dys-
function (Scherzer et al. 2012; Gupta et al. 2014; 
Jose et al. 2014). Association with PI/r and COBI 
could further increase these risks (DeJesus et al. 
2012; Young et al. 2012; Ryom et al. 2013; Baxi et al. 
2014; Clumeck et al. 2014; Mwafongo et al. 2014).
- Higher risk of bone mineral density (BMD) reduc-
tion compared to ABC/3TC (McComsey et al. 2010; 
Stellbrink et al. 2010).
→
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ARVs class Drug(s) Evidences of efficacy deriving from RCT Advantages Disadvantages
NNRTI EFV - Evaluated in association with both TDF/FTC and 
ABC/3TC.
- Evaluated in comparison studies against all other 
therapy combinations, except DRV/r.
- Not-inferior to RPV, ATV/r, and EVG/COBI (Co-
hen et al. 2011a; Molina et al. 2011; Cohen et al. 
2012; Cohen et al. 2013c; Nelson et al. 2013; Molina 
et al. 2014b).
- Superior to RPV (non STR) in patients with base-
line HIV viremia >100,000 copies/ml (Cohen et al. 
2011a; Molina et al. 2011; Cohen et al. 2012; Cohen 
et al. 2013c; Nelson et al. 2013; Molina et al. 2014b).
- Inferior to RAL in long term observation (Not 
inferior at the primary endpoint at 48 weeks) (Len-
nox et al. 2009; Rockstroh et al. 2013).
- Inferior to DTG (at 48 weeks) (Walmsley et al. 
2013).
- Once a day regimen.
- Available in co-formula-
tion with TDF/FTC.
- Extensive clinical use.
- Available as generic 
drug.
- Increased risk of resistance mutations at failure 
compared to PI/r and DTG (Riddler et al. 2008; 
Daar et al. 2011; Walmsley et al. 2013). Not recom-
mended in patients harbouring transmitted resis-
tance to NNRTIs.
- Use of EFV in the first six weeks of pregnancy has 
been associated to an higher risk of foetal malfor-
mations (neural tube defects); however in recent 
studies and meta-analysis the estimated risk of de-
veloping foetal malformations was not superior to 
other ARVs (Ford et al. 2014; Sibiude et al. 2014).
- Neurological and psychiatric effects (dizziness 
and trouble sleeping) mostly during the first 
months of treatment, with possible long term per-
sistence (Mills et al. 2013a).
- Use of EFV is associated to depression (not con-
firmed in all the studies), and higher risk of suicidal 
tendencies in RCT re-analysis (not confirmed by 
pharmacovigilance data) (Mollan et al. 2014; Napoli 
et al. 2015).
- Use of EFV is associated with a higher risk of de-
veloping dyslipidemia compared to RPV and inte-
grase inhibitors (INI) (Cohen et al. 2011a; Molina 
et al. 2011; Cohen et al. 2012; Cohen et al. 2013c; 
Nelson et al. 2013; Molina et al. 2014b) (Lennox et 
al. 2009; Cohen et al. 2013b; Rockstroh et al. 2013; 
Walmsley et al. 2013; Cohen et al. 2014).
- Use of EFV is associated with a higher risk of devel-
oping cutaneous rash compared other anchor drugs 
(Riddler et al. 2008; Lennox et al. 2009; Cohen et al. 
2011a; Daar et al. 2011; Molina et al. 2011; Cohen 
et al. 2012; Cohen et al. 2013a; Cohen et al. 2013c; 
Nelson et al. 2013; Rockstroh et al. 2013; Walmsley 
et al. 2013; Cohen et al. 2014; Molina et al. 2014a)
- Possible pharmacological interactions (EFV is a 
substrate and an inducer of CYP3A4).
- EFV should be taken at empty stomach, preferably 
at bedtime (meals significantly enhance EFV ab-
sorption and thus increase drug-related toxicities).
RPV - Evaluated mostly in association with TDF/FTC. 
Limited data available for the association with 
ABC/3TC.
- Evaluated in comparative studies against EFV.
- Not inferior to EFV if total, not stratified, popula-
tion is considered; inferior to EFV in patients with 
baseline viremia >100,000 copies/ml, with higher 
risk of developing resistance (Cohen et al. 2011a; Mo-
lina et al. 2011; Cohen et al. 2012; Cohen et al. 2013c; 
Nelson et al. 2013; Molina et al. 2014b). 
- Not inferior to EFV in STR with TDF/FTC in 
patients with baseline viral load >100,000 copies/
ml; superior efficacy in patients with baseline vi-
ral load <100,000 copies/ml (Cohen et al. 2013b; 
Cohen et al. 2014).
- Approved for use in patients naive to antiretrovi-
ral therapy only if baseline viremia is lower than 
100,000 copies/ml. Not recommended if CD4 T cell 
count is lower than 200 cells/µl due to the higher 
risk of virological failure and resistance.
- Once a day regimen.
- Available in co-formula-
tion with TDF/FTC.
- Good tolerability profile 
compared to the majority 
of other anchor drugs.
- Minor neuropsychiatric 
effects (dizziness, trou-
ble sleeping), cutaneous 
rash, and dyslipidemia 
compared to EFV (Cohen 
et al. 2011a; Molina et al. 
2011; Cohen et al. 2012; 
Cohen et al. 2013c; Nel-
son et al. 2013; Molina et 
al. 2014b) (Cohen et al. 
2013b; Cohen et al. 2014) 
(Mills et al. 2013a).
- Increased risk of resistance mutations at failure 
compared to EFV (Cohen et al. 2011a; Molina et al. 
2011; Cohen et al. 2012; Cohen et al. 2013c; Nelson 
et al. 2013; Molina et al. 2014b). Not recommended 
in patients harbouring transmitted resistance to 
NNRTIs.
- Possible pharmacological interactions (RPV is a 
substrate and an inducer of CYP3A4).
- Recommended administration with food.
- Co-administration of RPV with proton pump in-
hibitors is contraindicated
- Caution should be used when RPV is co-admin-
istered with H2 antagonists or drugs with known 
risk of torsade de pointes-type- arrhythmia.
→
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ARVs class Drug(s) Evidences of efficacy deriving from RCT Advantages Disadvantages
NNRTI EFV - Evaluated in association with both TDF/FTC and 
ABC/3TC.
- Evaluated in comparison studies against all other 
therapy combinations, except DRV/r.
- Not-inferior to RPV, ATV/r, and EVG/COBI (Co-
hen et al. 2011a; Molina et al. 2011; Cohen et al. 
2012; Cohen et al. 2013c; Nelson et al. 2013; Molina 
et al. 2014b).
- Superior to RPV (non STR) in patients with base-
line HIV viremia >100,000 copies/ml (Cohen et al. 
2011a; Molina et al. 2011; Cohen et al. 2012; Cohen 
et al. 2013c; Nelson et al. 2013; Molina et al. 2014b).
- Inferior to RAL in long term observation (Not 
inferior at the primary endpoint at 48 weeks) (Len-
nox et al. 2009; Rockstroh et al. 2013).
- Inferior to DTG (at 48 weeks) (Walmsley et al. 
2013).
- Once a day regimen.
- Available in co-formula-
tion with TDF/FTC.
- Extensive clinical use.
- Available as generic 
drug.
- Increased risk of resistance mutations at failure 
compared to PI/r and DTG (Riddler et al. 2008; 
Daar et al. 2011; Walmsley et al. 2013). Not recom-
mended in patients harbouring transmitted resis-
tance to NNRTIs.
- Use of EFV in the first six weeks of pregnancy has 
been associated to an higher risk of foetal malfor-
mations (neural tube defects); however in recent 
studies and meta-analysis the estimated risk of de-
veloping foetal malformations was not superior to 
other ARVs (Ford et al. 2014; Sibiude et al. 2014).
- Neurological and psychiatric effects (dizziness 
and trouble sleeping) mostly during the first 
months of treatment, with possible long term per-
sistence (Mills et al. 2013a).
- Use of EFV is associated to depression (not con-
firmed in all the studies), and higher risk of suicidal 
tendencies in RCT re-analysis (not confirmed by 
pharmacovigilance data) (Mollan et al. 2014; Napoli 
et al. 2015).
- Use of EFV is associated with a higher risk of de-
veloping dyslipidemia compared to RPV and inte-
grase inhibitors (INI) (Cohen et al. 2011a; Molina 
et al. 2011; Cohen et al. 2012; Cohen et al. 2013c; 
Nelson et al. 2013; Molina et al. 2014b) (Lennox et 
al. 2009; Cohen et al. 2013b; Rockstroh et al. 2013; 
Walmsley et al. 2013; Cohen et al. 2014).
- Use of EFV is associated with a higher risk of devel-
oping cutaneous rash compared other anchor drugs 
(Riddler et al. 2008; Lennox et al. 2009; Cohen et al. 
2011a; Daar et al. 2011; Molina et al. 2011; Cohen 
et al. 2012; Cohen et al. 2013a; Cohen et al. 2013c; 
Nelson et al. 2013; Rockstroh et al. 2013; Walmsley 
et al. 2013; Cohen et al. 2014; Molina et al. 2014a)
- Possible pharmacological interactions (EFV is a 
substrate and an inducer of CYP3A4).
- EFV should be taken at empty stomach, preferably 
at bedtime (meals significantly enhance EFV ab-
sorption and thus increase drug-related toxicities).
RPV - Evaluated mostly in association with TDF/FTC. 
Limited data available for the association with 
ABC/3TC.
- Evaluated in comparative studies against EFV.
- Not inferior to EFV if total, not stratified, popula-
tion is considered; inferior to EFV in patients with 
baseline viremia >100,000 copies/ml, with higher 
risk of developing resistance (Cohen et al. 2011a; Mo-
lina et al. 2011; Cohen et al. 2012; Cohen et al. 2013c; 
Nelson et al. 2013; Molina et al. 2014b). 
- Not inferior to EFV in STR with TDF/FTC in 
patients with baseline viral load >100,000 copies/
ml; superior efficacy in patients with baseline vi-
ral load <100,000 copies/ml (Cohen et al. 2013b; 
Cohen et al. 2014).
- Approved for use in patients naive to antiretrovi-
ral therapy only if baseline viremia is lower than 
100,000 copies/ml. Not recommended if CD4 T cell 
count is lower than 200 cells/µl due to the higher 
risk of virological failure and resistance.
- Once a day regimen.
- Available in co-formula-
tion with TDF/FTC.
- Good tolerability profile 
compared to the majority 
of other anchor drugs.
- Minor neuropsychiatric 
effects (dizziness, trou-
ble sleeping), cutaneous 
rash, and dyslipidemia 
compared to EFV (Cohen 
et al. 2011a; Molina et al. 
2011; Cohen et al. 2012; 
Cohen et al. 2013c; Nel-
son et al. 2013; Molina et 
al. 2014b) (Cohen et al. 
2013b; Cohen et al. 2014) 
(Mills et al. 2013a).
- Increased risk of resistance mutations at failure 
compared to EFV (Cohen et al. 2011a; Molina et al. 
2011; Cohen et al. 2012; Cohen et al. 2013c; Nelson 
et al. 2013; Molina et al. 2014b). Not recommended 
in patients harbouring transmitted resistance to 
NNRTIs.
- Possible pharmacological interactions (RPV is a 
substrate and an inducer of CYP3A4).
- Recommended administration with food.
- Co-administration of RPV with proton pump in-
hibitors is contraindicated
- Caution should be used when RPV is co-admin-
istered with H2 antagonists or drugs with known 
risk of torsade de pointes-type- arrhythmia.
→
ARVs class Drug(s) Evidences of efficacy deriving from RCT Advantages Disadvantages
PI/r ATV/r - Evaluated in association with either TDF/FTC or 
ABC/3TC.
- Evaluated in comparison studies against all other 
anchor drugs, except for RPV and DTG.
- Not inferior to EFV and EVG/COBI (Daar et al. 
2011; DeJesus et al. 2012; Clumeck et al. 2014).
- Equivalent to DRV/r and RAL (Landovitz et al. 
2014). 
- Once a day regimen.
- Lower risk of resistance 
mutations at failure com-
pared to NNRTI, EVG/
COBI, and RAL (Sax et 
al. 2009; Daar et al. 2011; 
DeJesus et al. 2012; Clu-
meck et al. 2014; Lando-
vitz et al. 2014).
- Extensive clinical use
- Co-formulations with other ARVs are not avail-
able.
- Risk of developing hyperbilirubinaemia and yel-
low jaundice. 
- Risk of developing gastro-intestinal adverse ef-
fects.
- Higher risk of discontinuation due to adverse 
events (indirect hyperbilirubinaemia; gastrointes-
tinal adverse effects) compared to DRV/r and RAL 
(Landovitz et al. 2014).
- Increased risk of kidney and gallbladder lithiasis.
- Increased risk of kidney failure and proximal re-
nal tubulopathy (if used in association with TDF) 
(DeJesus et al. 2012; Clumeck et al. 2014) (Young et 
al. 2012; Ryom et al. 2013).
- Higher risk of developing dyslipidemia compared 
to RAL and EVG/COBI (DeJesus et al. 2012; Clu-
meck et al. 2014; Landovitz et al. 2014).
- Higher risk of BMD reduction compared to RAL (if 
used in association with TDF) (Brown et al. 2014).
- Co-administration with proton pump inhibitors 
can reduce absorption of  ATV.
- Possible pharmacological interactions (ATV is a 
substrate and an inducer of CYP3A4).
- Recommended administration with food.
DRV/r - Evaluated in association with TDF/FTC. Associa-
tion with ABC/3TC has been evaluate in only one 
RCT.
- Evaluated in comparison studies against ATV/r, 
RAL, and DTG. Comparative studies against NN-
RTIs are missing.
- Equivalent to ATV/r and RAL (Landovitz et al. 
2014).
- Inferior to DTG (at primary endpoint at 48 
weeks) (Clotet et al. 2014).
- Once a day regimen.
- Lower risk of resistance 
mutations at failure com-
pared to NNRTI e INI 
(non DTG) (Ortiz et al. 
2008; Orkin et al. 2013; 
Landovitz et al. 2014).
- Lower risk of discon-
tinuation due to adverse 
events (indirect hyper-
bilirubinaemia; gastroin-
testinal adverse effects) 
compared to ATV/r 
(Landovitz et al. 2014).
- Extensive clinical use.
- Co-formulations with other ARVs are not avail-
able 
- Higher risk of developing cutaneous rash com-
pared to other drugs of the same class (Ortiz et al. 
2008; Orkin et al. 2013).
- Risk of developing gastro-intestinal adverse ef-
fects.
- Higher risk of developing dyslipidmia and BMD 
reduction compared to RAL (if used in association 
with TDF).
- Possible pharmacological interactions (DRV/r is a 
substrate and an inducer of CYP3A4).
- Administration with food is recommended.
INI RAL - Evaluated in comparative studies against all oth-
er recommended anchor drugs except RPV and 
EVG/COBI.
- Superior to EFV in long term studies (not inferior 
at the primary end point at 48 weeks) (Lennox et 
al. 2009; Rockstroh et al. 2013).
- Equivalent to ATV/r and DRV/r (Superior to both 
drugs at the combined endpoint of tolerability and 
effectiveness) (Landovitz et al. 2014).
- Not-inferior to DTG if the total (not stratified) 
population is considered; inferior to DTG in long 
term studies (96 weeks) in patients with baseline 
viremia >100.000 copies/ml (Raffi et al. 2013a; Raf-
fi et al. 2013b).
- Improved lipidic profile 
compared to PI/r and 
EFV (Lennox et al. 2009; 
Rockstroh et al. 2013; 
Ofotokun et al. 2014).
- Lower risk of BMD 
reduction compared to 
ATV/r and DRV/r (if used 
in association with TDF) 
(Brown et al. 2014).
- No food-drug interac-
tions reported.
- No CYP3A4-related 
pharmacological inter-
action.
- Extensive clinical use.
- Twice a day regimen
- Co-formulations with other ARVs are not avail-
able.
- Evaluated in association with TDF/FTC. Associ-
ation with ABC/3TC has been evaluate only in one 
- RCT (Raffi et al. 2013a; Raffi et al. 2013b).
- Increased risk of resistance mutations at failure 
compared to IP/r or DTG (Raffi et al. 2013a; Raffi 
et al. 2013b; Landovitz et al. 2014).
- Increase risk of elevated levels of creatinkinase, 
myopathy e rhabdomyolysis (Lee et al. 2013) (Mer-
ck Sharp & Dohme Corp 2015).
- HSR has been reported (including SJ syndrome) 
(Merck Sharp & Dohme Corp 2015).
- Antacids containing metals significantly decrease 
RAL plasma levels. Co-administration of alumi-
num or magnesium hydroxide-containing antacids 
and RAL is not recommended. CaCO3 antacids are 
recommended as an alternative.
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INI EVG/
COBI
- Evaluated in comparative studies against only 
EFV and ATV/r.
- Not inferior to EFV (DeJesus et al. 2012; Sax et 
al. 2012; Clumeck et al. 2014; Wohl et al. 2014) and 
ATV/r (in association with TDF/FTC) (DeJesus et 
al. 2012; Clumeck et al. 2014).
- Once a day regimen.
- Available in co-formula-
tion and STR with TDF/
FTC.
- Improved lipidic pro-
file compared to EFV 
and ATV/r (associated to 
TDF/FTC) (DeJesus et al. 
2012; Sax et al. 2012; Clu-
meck et al. 2014; Wohl et 
al. 2014).
- Available in association with TDF/FTC only.
- Contraindicated if CRCL <70 ml/min
- Increased risk of resistance mutations at failure 
compared to PI/r or DTG (DeJesus et al. 2012; Sax 
et al. 2012; Clumeck et al. 2014; Wohl et al. 2014).
Contraindicated in patients with impaired renal 
function (GFR <70 mL/min/1.73 m2).
- Use of ETG/COBI has been associated to an 
higher risk of kidney failure and proximal renal 
tubulopathy (DeJesus et al. 2012; Sax et al. 2012; 
Clumeck et al. 2014; Wohl et al. 2014).
- COBI affects creatinine active tubular secretion 
and its use can increase serum creatinine and GFR 
without an effect on glomerular filtration (German 
et al. 2012).
- Possible pharmacological interactions (COBI is a 
strong inhibitor of CYP3A4).
- Co-administration of aluminium or magnesium 
hydroxide-containing products and ETG/COBI is 
not recommended since polyvalent cations might 
interfere with absorption.
- Administration with food is recommended
- Limited real life data available.
DTG - Evaluated in association both with TDF/FTC and 
with ABC/3TC.
- Evaluated in comparative studies against all oth-
er recommended anchor drugs except RPV, ATV/r, 
and EVG/COBI.
- Superior to EFV and DRV/r. (at primary endpoint 
at 48 weeks) (Walmsley et al. 2013; Clotet et al. 
2014).
- Not-inferior to RAL if the total (not stratified) 
population is considered; superior to RAL in long 
term studies (96 weeks) in patients with baseline 
viremia >100.000 copies/ml (Raffi et al. 2013a; Raf-
fi et al. 2013b).
- Demonstrated virological efficacy regardless of 
the associated drugs (TDF/FTC or ABC/3TC) and 
plasma HIV RNA at baseline.
- Once a day regimen.
- Available in co-formu-
lation and STR with AB-
C/3TC.
- Risk of resistance mu-
tations at virological 
failure similar to Pi/r and 
lower than NNRTIs and 
other INIs (Raffi et al. 
2013a; Raffi et al. 2013b; 
Walmsley et al. 2013; Clo-
tet et al. 2014).
- Better tolerability com-
pared with the majority 
of anchor drugs.
- Improved lipidic pro-
file compared to EFV e 
DRV/r (Walmsley et al. 
2013; Clotet et al. 2014).
- No food-drug interac-
tions reported.
- No reported CYP3A4- 
dipendent interaction.
- DTG affects creatinine active tubular secretion 
and its use might increase serum creatinine and 
GFR without an effect on glomerular filtration.
- Co-administration of aluminium or magnesium 
hydroxide-containing products and DTG is not 
recommended since polyvalent cations might in-
terfere with absorption.
- DTG is a substrate of uridine diphosphate glucu-
ronosyltransferase.
- Limited real life data available.
compared to other molecules of the same drug 
class.
Randomized clinical trials which have been 
completed through the primary endpoint sug-
gest that the combination PI/r/3TC/FTC might 
be graded as highly recommended [AI] in pres-
ence of NRTIs associated toxicity and moder-
ately recommended [BI] to prevent NRTI asso-
ciated toxicity. 
Dual therapies lacking a PI/r are not recom-
mended to date since clinical trials which eval-
uated these regimens lack the adequate robust-
ness and their results are not encouraging in 
terms of efficacy. 
Monotherapy (Tables 8, 9). Several studies have 
evaluated the switch from a standard therapeu-
tic regimen to a monotherapy consisting of a 
PI/r. The rationale supporting these strategies 
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is to limit or prevent NRTI associated toxicity 
while, at the same time, reducing the treatment 
costs. 
The preliminary results of the biggest RCT 
evaluating monotherapy efficiency have been 
recently published (PIVOT study, including 587 
patients). The aim of this study was to show the 
non-inferiority of monotherapy with PI/r com-
pared to the conventional triple therapy; prima-
ry endpoint was loss of future treatment options 
based on development of drug resistance. After 
3.5 years of follow up this study indicates that 
monotherapy with PI/r is associated with 35% 
risk of virological failure (vs 3% of patients in 
triple treatment arm), does not induce clinical 
events, promotes a slight reduction of grade 3-4 
adverse events (46% vs 55%, p=0,04), does not 
reduce the range of therapeutic options avail-
TABLE 7 - Summary of rationale/advantages/disadvantages of dual therapy for treatment optimization.
Class of 
optimization
AIM Potential 
advantages
Potential 
disadvantages
Rate of 
recommendation
Related literature
From a 
combination of 
three drugs to 
a PI/r + NNRTI 
regimen (a)
Reduce/Prevent 
NRTI associated 
toxicity
Demonstrated 
virological efficacy in 
subjects not eligible 
for simplification to 
monotherapy
In case of virological 
failure, development 
of resistance towards 
the newly introduced 
therapeutic class. NNRTI 
associated toxicity
[CI] (Negredo et al. 2009; 
Negredo et al. 2013)
From a 
combination of 
three drugs to 
DRV/r or LPV/r + 
RAL (b)
Reduce/Prevent 
NRTI associated 
toxicity
Demonstrated 
virological efficacy in 
subjects not eligible 
for simplification to 
monotherapy
Development of resistance 
towards the newly 
introduced therapeutic 
class (in case of virological 
failure); metabolic profile 
impairment(d)
[BI] in presence of 
NRTI toxicity or 
[CI] as a preventive 
measure
(Ofotokun et al. 2012; 
Nishijima et al. 2013; 
Madeddu et al. 2014; 
Van Lunzen et al. 2014)
From a 
combination of 
three drugs to a 
PI/r + 3TC or 
FTC (c)
Reduce/Prevent 
NRTI associated 
toxicity
Demonstrated 
virological efficacy in 
subjects not eligible 
for simplification to 
monotherapy
Increased toxicity [AI] ] in presence 
of NRTI toxicity 
(excluding 3TC/
FTC) or [BI] as a 
preventive measure
(Di Giambenedetto
et al. 2013;  
Borghetti et al. 2014; 
Gianotti et al. 2014a; 
Perez-Molina et al. 2014) 
a) Few clinical trials evaluated this regimen testing an association no longer in use in clinical practice (LPV/r + NVP). Based on the known phar-
macokinetic properties, it is reasonable to expect similar results for the association DRV/r + ETR or RPV, however no robust experimental data 
for this association have been produced so far. Similarly, there is no clear evidence supporting the reduction of NRTI associated toxicities. b) 
KITE study: clinical study involving 60 subjects with suppressed HIV replication, randomized (2:1) to switch to LPV/r 400/100 mg BID + RAL 
400 mg BID or to continue on previous cART regimen. At week 48, 92% of the LPV/r + RAL arm and 88% of the control arm had maintained 
HIV RNA>50 copies/ml. Patients who switched to LPV/r + RAL showed a significantly higher triglyceridemia. SPARE study: 58 patients with 
plasma HIV RNA<50 copies/ml in treatment with LPV/r+TDF/FTC at the moment of enrollment, randomized (1:1) to switch to DRV/r + RAL or 
to continue the previous cART regimen. 100% of patients included in arms showed virological suppression at week 48; Tenofovir tubulopathy 
showed significant improvement in the RAL+DRV/r compared with both LPV/r+TVD HARNESS study: 109 patients with virologic suppres-
sion were randomized (2:1) to switch from a triple-drug regimen including 2 NRTIs to ATV/r 300/100mg once daily +RAL 400 mg twice daily. 
At week 24, plasma HIV RNA below the limit of detection occurred in 80.6% in the ATV/r + RAL arm and in 94.5% of patients in the ATV/r 
+ TDF/FTC arm. At 48 weeks (secondary endpoint) virological suppression occurred in 69.4% and 86.5% of patient, in the ATV/r + RAL arm 
and in the ATV/r + TDF/FTC arm, respectively. A retrospective study (ICONA) considering 101 patients with suppressed viremia who started a 
new therapeutic regiment with DRV/r + RAL estimated a relatively low risk (13% at 1 year, 16% at 2 years) of therapeutic failure (virological 
failure or discontinuation due to toxicity). Risk of virological failure was slightly higher for the patients with higher baseline HIV RNA levels. 
Reductions in NRTI associated toxicity were not demonstrated. c) SALT study: 286 patients with HIV RNA of less than 50 copies/ml for at least 
6 months were randomized (1: 1) to dual treatment with ATV/r+3TC or triple treatment ATV/r+2NRTIs . At week 48 (primary endpoint) virolo-
gical suppression (HIV RNA<50 copies/ml) was observed in 83% of patients in the ATV/r+3TC arm and 78.4% of patients in the ATV/r+2NRTIs 
arm demonstrating non-inferiority (difference: +5.2%; 95%CI 15.2% -4.8%). In the ATLAS-M study, the interim analysis (24 weeks) performed 
on 124 patients randomized to switch to ATV/r+3TC or to maintain the original three-drug regimen, showed 5.7% treatment failure in the ATV/
r+3TC arm and 14.1% in the ATV/r + 2NRTIs arm. Treatment with ATV/r + 3TC was associated to an improved recovery of CD4 T cell counts 
and kidney function, and with a slight impairment of the lipidic profile. Finally, in the ATLAS study, among 40 patients with plasma HIV RNA 
<50 copies/ml switching from ATV/r + 2NRTI to a treatment with ATV/r + 3TC, one had virological failure and four patients reported kidney 
colic pain. Kidney function was improved overall, however the study reported an impairment of the lipidic profile. 
Study OLE: HIV infected patients with <50 copies/ml for at least six months on triple therapy with LPV/r + 3TC or FTC and a third nucleos(t)
ide were randomized (1:1) to switch to DTG with LPV/r and 3TC or continue triple therapy. Dual therapy regimen proved to be not inferior to 
triple therapy, with three virological failures for each arm, similar rate of adverse effects and slight impairment of lipidic profile in the dual 
therapy regimen arm. Two small retrospective studies have recently shown that optimization using DRV/r + 3TC or FTC does not involve a 
significant risk of virological failure, while being associated to an improvement of kidney function (in particular in patients under TDF tre-
atment); impairment of lipidic profile was observed also in these studies. d) The switch to the combination ATV/r + RAL is associated with a 
higher risk of virological rebound and therefore is not recommended.
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able for future switching, and has a favourable 
cost-effect profile.
A recent meta-analysis evaluating efficacy of 
DRV/r or LPV/r in several RCTs (n=1553) es-
timated a -7% differential difference (95%CI. 
-11% -4%) for the occurrence of virological fail-
ure between patients switching to monotherapy 
with PI/r and patients maintaining standard tri-
ple therapy (return to NRTI based regimen was 
considered assimilate to virological failure). If 
return to previous regimens was not considered 
as failure, the estimated difference between the 
two arms was 0% (95% CI -3% +3%).
Several different variables have been investi-
gated in randomized, observational, and me-
ta-analysis studies as possible predictors of vi-
rological failure after switch to PI/r monothera-
py. Low nadir CD4 T cell count, low therapy ad-
TABLE 8 - Summary of rationale/advantages/disadvantages of monotherapy for treatment optimization.
Class of 
optimization
AIM Potential 
advantages
Potential 
disadvantages
Rate of 
recommendation
Related literature
From dual or 
triple therapy to 
LPV/r 400/100 mg 
BID (a)
Reduce/Prevent 
NRTI associated 
toxicity
Favourable 
cost-
effectiveness 
ratio
Increase pill burden except for 
patients coming from a LPV/r + 
2NRTI regimen; adverse gastro 
enteric events; and increased long-
term cardiovascular risk; lower 
virological efficacy; unclear results 
concerning virological efficacy in 
HIV sanctuaries, contraindicated in 
HBsAg positive patients
[AI] in presence 
of NRTI toxicity 
or [CI] as a 
preventive 
measure
(Cameron et al. 2008; 
Arribas et al. 2009; 
Bierman et al. 2009; 
Pulido et al. 2009; 
Gutmann et al. 2010; 
d’Arminio Monforte 
et al. 2014; Gianotti 
et al. 2014b; Pinnetti 
et al. 2014) 
From dual or 
triple therapy to 
DRV/r 800/100 
mg QD or DRV/r 
600/100 mg BID 
(b)
Reduce/Prevent 
NRTI associated 
toxicity
Favourable 
cost-
effectiveness 
ratio
Unclear results concerning 
virological efficacy in HIV 
sanctuaries, contraindicated in 
HBsAg positive patients
[AI] in presence 
of NRTI toxicity 
or [CI] as a 
preventive 
measure
(Gianotti et al. 2014b; 
Pinnetti et al. 2014) 
(Arribas et al. 2012; 
Valantin et al. 2012; 
Geretti et al. 2013; 
Antinori et al. 2014) 
From dual or 
triple therapy to 
ATV/r 300/100 mg 
QD (c)
Reduce/Prevent 
NRTI associated 
toxicity
Favourable 
cost-
effectiveness 
ratio
Lower virological efficiency, in 
particular in HCV co-infected 
patients with baseline plasma HIV 
RNA >100,000 copies/ml. Unclear 
results concerning virological 
efficacy in HIV sanctuaries, 
contraindicated in HBsAg positive 
patients
[AI] in presence 
of NRTI 
toxicity . Not 
recommended 
as preventive 
measure
(Swindells et al. 2006; 
Karlstrom et al. 2007; 
Spagnuolo et al. 2014)
a) Studies involving the switch to LPV/r provided heterogeneous data, depending on trial design and type of statistical analysis. However, 
these studies have shown that in some cases virological non inferiority compared to triple therapy was not achieved, that primary mutations 
conferring resistance to PI were present at virological failure, and that reintroduction of the two NRTIs resulted in suppression of viremia 
in almost all the cases of virological failure. Among the factors which can predict failure, some authors have identified low nadir CD4 T cell 
count, reduced adherence to therapy, levels of HIV DNA (no predictive threshold was identified), absence of LPV/r in the previous regimens, 
and a short virological suppression interval before the switch. HCV coinfection does not correlate with virological failure. In the PRIMO 
study, administration of LPV/r 800/200 mg twice a day has been associated with an higher risk of virological failure compared to the triple 
regiment (PI/r + 2NRTI) and is therefore contraindicated. b) The clinical trials MONET and PROTEA evaluated the switch to DRV/r at 800/100 
mg dosage once a day, whereas the MONOI study investigated the 600/100 mg dosage once a day. In MONET and MONOI, virological non 
inferiority compared to control regimen (DRV/r + 2NRTI) at 48 weeks was achieved. In the MONOI study, non inferiority was achieved in per 
protocol analysis, but not in the intent -to-treat analysis, even if 96weeks after switching non inferiority was confirmed in all the analysis. In 
the MONET trial non inferiority was determined using a different type of analysis, but was not confirmed in the main analysis (ITT, TLOVR, 
Switch=Failure) at 96 weeks when non inferiority was maintained only if patient who reverted to a standard triple therapy were not included 
in the failed patient group. This data is confirmed at 144 weeks and underlines how HIV/HCV co-infection contributes to virological failure 
of DRV/r based monotherapy. In the PROTEA study, switch to DRV/r at 800/100 mg/day did not meet criteria for non inferiority in the general 
analysis (-8.7%; 95% CI -1.8% -15.5%), whereas in a post-hoc analysis a difference in efficacy between DRV/r and the control arm was obser-
ved only in patients with a CD4 T cell nadir lower than 200 cells/µl. In the same study, no difference between treatment groups was observed i 
terms of neurocognitive performances. No differences were observed in the subset of HCV co-infected patients included in the study. Results 
of the PIVOT study (see also general introduction) regard mainly DRV/r monotherapy since this therapeutic regimen was used in 80% of 
study participants. c) Since 2006 contrasting data deriving from non comparative studies were made available. The sole randomized clinical 
study lasting 96 weeks (MODAt) was interrupted for virological inferiority compared to triple therapy at week 48; long term analysis at week 
96 did not demonstrated non inferiority (64% efficacy in the ATV/r arm vs 63% in ATV/r + 2NRTI arm, +1.3%; 95% CI -17.5% 20.5%). Higher 
risk of virological failure in HCV co-infected patients and patients with baseline plasma HIV RNA >100.000 copies/ml; monotherapy showed 
a better safety profile, but needs to be evaluated in long-term therapies.
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TABLE 9 - Summary of rationale/advantages/disadvantages of monotherapy, fixed dose combination  
and single tablet regimens for treatment optimization.
Class of 
optimization
AIM Potential advantages Potential disadvantages Rate of 
recommendation
Related literature
From NVP BID 
to RPV (a)
Improve 
adherence
Slight reduction of eGFR 
(uncertain clinical relevance)
[BIII] (Allavena et al. 2014; 
Mora-Peris et al. 2014)
From EFV 
to RPV (b)
Reduce/
prevent 
toxicity
Lower metabolic 
impact and 
improvement of EFV 
associated neurological 
symptoms
Slight reduction of eGFR 
(uncertain clinical relevance)
[BIII] (Mills et al. 2013b)
From NNRTI 
to EVG/COBI/
FTC/TDF (c)
Reduce/
prevent 
toxicity
Lower incidence 
of adverse events 
targeting SNC; 
slight metabolic 
improvement
Slight reduction of eGFR 
(uncertain clinical relevance)
[AI] (Pozniak et al. 2014)
From PI/r to 
EFV (d)
Reduce/
prevent 
toxicity
Available in co-
formulation; reduced 
gastrointestinal 
adverse effects
Increased incidence of adverse 
events, in particular targeting 
DN. Lower genetic barrier
[AI] (Martinez et al. 2007; 
Dejesus et al. 2009)
From PI/r to 
NVP (d)
Reduce/
prevent 
toxicity
Reduced 
gastrointestinal 
adverse effects and 
lower metabolic 
impact
Short-term skin and liver 
toxicity. 
Lower genetic barrier
[AI] (Martinez et al. 2007; 
Dejesus et al. 2009)
From PI/r to 
TDF/FTC/RPV (e)
Reduce/
prevent 
toxicity
Reduced 
gastrointestinal 
adverse effects and 
lower metabolic 
impact
Lower genetic barrier [AI] (Palella et al. 2014) 
From PI/r 
to RAL (f)
Reduce/
prevent 
toxicity
Reduced 
gastrointestinal 
adverse effects and 
lower metabolic 
impact
Lower genetic barrier; non 
inferiority was not reached in 
one of the studies; twice a day 
regimen; not recommended 
in presence of previous failure 
to NRTI; start at least 6 weeks 
after achieving virological 
suppression
[BI] (Eron et al. 2010; 
Martinez et al. 2010; 
Curran et al. 2012)
From PI/r to EVG/
COBI/FTC/TDF (g)
Reduce/
prevent 
toxicity
Improved virological 
suppression
Lower genetic barrier (?) [AI] (Arribas et al. 2014)
a) A single centre open-label study demonstrated maintenance of virological suppression without any virological failure at week 24 in 29 out 
of 32 patient who switched from TDV/FTC + NVP to TDV/FTC/RPV. b) In a single centre open-label non comparative study evaluating 49 
patients treated with EFV/FTC/TDF (STR), 93% of patients maintained virological suppression after switching to RPV/FTC/TDF (STR). Two 
patients reported virological failure. c) Virological non-inferiority (93% vs 88%) at week 48 was demonstrated in a randomized clinical trial 
enrolling 434 patients switching to STR containing EVG/COBI/FTC/TDF. The simplified arm showed less SNC abnormalities, a tendency to 
eGFR increase, and a reduction of metabolic impact compared with the control arm (NNRTI based therapy). d) NEFA study evaluated the 
efficacy of NVP, EFV or ABC as a substitute for a PI in a group of 498 patients. Switching to EGV or NVP was more effective in maintaining 
virological suppression, however discontinuation due to adverse events was more frequent with NNRTIs. e)In the SPIRIT multicentre clinical 
trial, 476 virologically suppressed HIV patients were randomized (2:1) to switch to TDV/FTC/RPV immediately or at week 24. Through 24 
weeks, switching to RPV/FTC/TDF was non-inferior to remaining on PI+RTV+2NRTIs and resulted in a slight increase of eGFR and in an 
improvement of lipidic profile. At week 48, 89.3% of patients in the simplification arm maintained virological suppression. f) Non inferiority 
was not observed in a randomized clinical trial evaluating the switch from LPV/r to RAL in virologically suppressed patients (SPIRAL). The 
factors mainly associated with virological failure were the presence of previous failures and thus, likely, presence of mutations conferring 
resistance to NRTI. A second randomized clinical trial has shown virological non-inferiority, likely because of a longer period of suppression 
before the switch (at least six months). Both studies have shown a favourable impact on lipid profile, while in SPIRAL study use of RAL signi-
ficantly reduced statin consumption and improved bone mineral density. g) A randomized clinical trial evaluating the effects of therapeutic 
simplification to a STR including EVG/COBI/FTC/TDF showed superiority in terms of viral suppression at week 48 compared to control 
group (antiretroviral therapy based on PI) (94% vs 87%).
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herence, limited duration of either the previous 
antiretroviral treatment or the viral suppres-
sion were all associated with an increased risk 
of failure. The most accurate parameter pre-
dicting virological failure was nadir CD4 T cell 
count. Increased risk of failure was associated 
with nadir CD4 T cell counts <100 cells/ml in 
the OK-4 study, and to nadir CD4 T cell counts 
<200 cells/ml in the MOST and PROTEA stud-
ies. Is then advisable to consider a nadir CD4 T 
cell count above 200 cells/ml as the threshold to 
select HIV patients eligible for DRV/r or LPV/r 
monotherapy.
The association between failure to monothera-
py and HCV was confirmed in the MODAT and 
MONET studies which evaluated the effect of 
switch to monotherapy with ATV/r and DRV/r, 
respectively. However, other studies such as the 
MONOI, PROTEA and PRIMO as well as the 
studies including LPV/r failed to identify this 
association and do not support the presence 
of HIV/HCV coinfection as a predictor of PI/r 
monotherapy response. 
Additional factors which showed ability to pre-
dict virological failure only in some studies 
where higher level of basal HIV viremia (HIV-
RNA >1 copy/ml o >5 copies/mL in MONOI e 
MONET studies, respectively) and basal HIV 
DNA levels (MONOI e MONET studies).
Increase in viral replication in cerebrospinal 
fluid (CSF) was sporadically reported in some 
patients enrolled in MOST MONOI and MON-
ET studies, leading to the hypothesis of a pos-
sible association between neurocognitive im-
pairment and PI/r monotherapy. However the 
analysis of the two RCT (PIVOT and PROTEA) 
in which neurocognitive assessment was in-
cluded in the trial evaluation scheme, did not 
confirm the existence of an increased risk of 
neurocognitive impairment during PI/r mono-
therapy. Additional observational studies, both 
cross-sectional and longitudinal, have further 
confirmed the latter finding ruling out the ex-
istence of a correlation between neurocognitive 
impairment and monotherapy. 
Nevertheless, viral replication in CSF was ob-
served in multiple clinical trials, although in a 
negligible fraction of patients [9 (1%) patients 
out of 800 switching to DRV/r or ATV/r mono-
therapy as reported in a recent meta-analysis]. 
In the study PROTEA, virological rebound in 
CSF was observed in 1 out 21 patients in the 
DRV/r monotherapy arm and in 0 out 19 pa-
tients in the DRV/r + 2NRTIs arm. 
Switch to LPV/r BID o DRV/r QD o BID might 
be recommended in patients experiencing 
NRTI toxicity [AI] or represent a therapeutic 
option to prevent NRTI related toxicity [CI]. To 
be eligible for switch to LPV/r od DRV/r mono-
therapy patients should be already in treatment 
with PI, with no clinical history of virological 
failure during PI treatment, show no evidence 
of mutation conferring resistance to PI, have 
plasma HIV RNA <50 copies/ml for at least 12 
months, and nadir CD4 T cell count >200 cells/
µL. Monotherapy using ATV/r might be con-
sidered in patients experiencing NRTI related 
toxicity who are not eligible for DRV/r or LPV/r 
combination [BI]. 
Data deriving from RCT indicate HIV/HCV 
coinfection is a predictive factor for virologi-
cal failure in patients switching to monother-
apy with ATV/r, but not with LPV/r while for 
DRV/r results are controversial Nevertheless, 
in absence of more robust data, PI/r mono-
therapy does not guarantee a sufficient levels 
of efficacy and safety in HIV/HCV coinfected 
individuals.
Regardless of the specific group of patients, for 
patients switching to Pi/r monotherapy a close 
monitoring, including HIV viral load monitor-
ing every three months, is mandatory in order 
to rapidly identify possible virological failure 
and to implement strategies for checking pa-
tient’s therapy adherence [AIII]. At virological 
rebound, defined as two consecutive HIV RNA 
measurements above 50 copies/ml in plasma, it 
is recommended to perform a genotypic resis-
tance test [AIII], possibly also on DNA, and the 
return to the traditional triple therapy [AIII].
Pill burden reduction: Fixed dose combina-
tions (FDC), once daily regimens, and single 
tablet regimens (STR) are therapeutic resourc-
es developed in order to reduce regimen com-
plexity and promote adherence in clinical prac-
tice. 
• FDC provide fixed concentrations for drugs 
combinations which are preferred over 
non-standardized combinations.
• Once daily regimens: daily intake (QD) (op-
posed to twice a day regimens - BID).
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• Single tablet regimens: co-formulations of 
multiple drugs in the same tablet.
Switching from PI to a different antiretroviral 
class (NNRTI or INI), i.e. from a regimen with 
a very high genetic barrier to a regimen with a 
minor genetic barrier, is recommended to im-
prove therapy tolerability. 
However this therapeutic choice is appropriate 
only for patients who have never experienced 
virological failure or assumed NRTI at subop-
timal concentrations or presented mutation 
associated with NRTI resistance (and NNRTI if 
the switch involves this class of drugs) [AI]. 
Moreover, in case of a new regimen including 
RAL, a minimum of 6 months of virological 
suppression are required to switch.
TABLE 10 - Strategic actions to enhance retention in care.
General principle Intervention Rate of 
recommendation
Related literature
Retention in care is associated 
with improved long-term 
survival.
- Inform the patients about the advantages of  
antiretroviral therapy adherence and regular counselling.
- Monitor retention in care for all the individuals in the 
follow-up population.
[AII] (Hall et al. 2013; 
Crawford 2014; 
Crawford et al. 2014; 
Nachega et al. 2014; 
Yehia et al. 2014)
Retention in care is essential 
in order to prevent virological 
failure, achieve immunological 
recovery and reduce the risk of 
transmission. 
At each visit:
- Define, together with the patient, the diagnostic work up 
and therapeutic course.
- Verify the patient’s comprehension.
If scheduled appointments are missed.
- Identify reasons for missed appointments. 
- Develop, together with the patient, a strategy to remove 
structural barriers preventing appointment adherence.
- Multidisciplinary education and counselling intervention 
approaches are recommended.
[AII] (Gardner et al. 2011; 
Horberg et al. 2013; 
Gardner et al. 2014)
Retention in care is achieved 
through the co-operation of a 
group of different professional 
figures.
- Integrate competencies and experiences from different 
professional figures. 
- Adopt an empathic approach.
- Customize interventions based on the specific needs of 
the patient.
- Reinforce motivation and involve the patient in the 
establishment of the therapeutic course.
[BII] (Gardner et al. 2011; 
Hall et al. 2013; 
Horberg et al. 2013; 
Gardner et al. 2014)
The highest risk of loss at 
follow up is occurs during the 
following periods:
- The observational period 
between diagnosis and start of 
therapy.
- The first months after therapy 
start.
- Optimize HIV counselling starting from the diagnosis of 
HIV infection.
- Provide the necessary information before starting 
antiretroviral therapy.
- Tune the diagnostic work up and the therapeutic 
flow to the different phases of infection (i.e. schedule 
more frequent appointments at the beginning of cART 
treatment).
- Provide psychological support.
[BII] (Gardner et al. 2011)
Risk factors associated with 
poor retention in care are more 
common in some groups of 
patients.
- Increase awareness for the following situations:
- Young age.
- Drug or alcohol addictions.
- Psychiatric diseases.
- Previous incarceration.
- Transgenders.
- Collaborate with complementary health care 
professionals.
[CIII] (Crawford et al. 2014)
The current methodological 
approach to determine retention 
in care is not standardized and 
needs to be adjusted to the 
specific clinical setting.
- Record missed appointments.
- Check appointment adherence, regular testing, and 
medication pick up.
[AII] (Brennan et al. 2014)
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RETENTION IN CARE
Retention in care is one of the fundamental 
steps included in the continuum of care, a con-
cept recently introduced in the HIV field to 
describe the process from diagnosis of a new 
infection (HIV testing), to connection with a 
health care provider (linkage of care), start and 
adherence to antiretroviral therapy (engage-
ment in care) and achievement and mainte-
nance of viral suppression.
Similarly to what observed for other chronic 
diseases, continuum of care for HIV:
• Is a fundamental factor to achieve and 
maintain the therapeutic goals, necessary to 
guarantee patients quality of life (Nachega 
et al. 2014).
• It can be considerate a surrogate marker to 
measure the quality of health care assistance 
(Crawford et al. 2014).
• In the context of HIV infection, continuum 
of care is a powerful tool to reduce new in-
fections and control the spread of epidemics 
(Crawford 2014).
Retention in care of HIV infected persons un-
der antiretroviral treatment is strongly depen-
dent on the creation of a favourable environ-
ment where all the health care players work 
cooperatively to successively connect and ac-
tively engage HIV patients. 
In this process, providing an emphatic ap-
proach and the ability to tailor antiretrovi-
ral regimen in view of the specific situation 
of each patients are favourable elements to 
achieve retention in care (Tables 10, 11). 
TABLE 11 - Interventions to enhance retention in care and re-linkage.
General principle Intervention Rate of
recommendation
Related literature
Improving health care 
practitioner-patient relationship 
increases the chances of 
retention in care.
[BI] (Brennan et al. 2014)
Nurses might play a fundamental 
role for retention in care.
- Educate nurses and health personnel involved in 
the everyday activity in health care institutions on 
the importance of antiretroviral therapy adherence.
- Inform the patient on the steps of the diagnostic 
and therapeutic process.
- Check adherence to therapy.
- Implement an appointment reminder system.
[BI] (Raper 2014)
Relationships with health care 
professionals, and social support 
networks promote engagement 
in care.
- For patients displaying psychological distress 
due to social isolation, linkage with associations of 
people living with HIV is recommended in order to 
provide them assistance during the initial stages of 
the therapeutic process.
- Promote communication and understanding.
- Decrease social isolation.
[BI] (Thompson et al. 2012; 
Stricker et al. 2014)
Appointment reminder system. - Call (or email/text) the patient few days before the 
next scheduled appointment.
[BI] (Thompson et al. 2012)
Develop an active program for 
re-linkage to care for the patients 
who are lost to follow up.
- Get in touch with the patient.
- Identify and propose a strategy to overcome the 
barriers preventing retention in care.
- Define, together with the patient, the diagnostic 
work up and therapeutic course.
- Offer psychological support to the patient (medical 
specialists and structured groups programs).
[CIII] (Thompson et al. 2012)
Reduce waiting times for 
appointments.
- Provide the opportunity to perform diagnostic 
tests or visits outside the scheduled appointments.
- Schedule the next appointment at the end of the 
visit.
[CIII] (Thompson et al. 2012; 
Stricker et al. 2014)
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Estimates for continuum in care in Italy 
(2012) 
A model recapitulating the projections for the 
continuum in care in Italy has been recently 
developed 2012 (Girardi 2014). 
The number individuals living with HIV in Ita-
ly equals to 130,000, of whom 15% is not aware 
of his/her seropositive status (Mammone et al. 
2014). Of the 110,000 diagnosed individuals, 
15% is not retained to care (Lazzaretti et al. 
2012), thus the total number of HIV infected 
persons connected to health care providers is 
94000. Of them, about 13% is not under treat-
ment (Raimondo et al. 2013). Based on epide-
miological studies performed in Italy (ICONA 
Foundation - Italian Cohort Naive Antiretrovi-
rals), it might be estimated that 73,000 of the 
82,000 individual in therapy have reached vi-
ral suppression. 
As a consequence, in Italy, only 54% of per-
sons living with HIV has achieved virological 
suppression.
THE USE OF NEW ANTI HCV DRUGS 
FOR THE THERAPEUTIC MANAGEMENT 
OF HIV/HCV INFECTED PATIENTS
In all the patients with chronic hepatitis C in-
fection the opportunity to implement a phar-
macological treatment based on direct antiviral 
drugs alone or in combination with pegylated 
interferon and ribavirin must be considered 
(Table 12) (Association for the Study of Liver 
Diseases (AASLD) and International Antiviral 
Society-USA (IAS-USA); European AIDS Clini-
cal Society (EACS) 2014; European Association 
for the Study of the Liver 2014). If efficacy is 
similar, therapies interferon free must be pre-
ferred (European Association For The Study 
Of The Liver 2014). Tables 13 to 16 provide an 
overview of the therapeutic indications for dif-
ferent drugs and groups of patients, please re-
fer to Table 17 for the rating schemes of levels 
of recommendation and degree of evidence for 
HCV studies.
TABLE 12 - Indications for treating HIV/HCV coinfection.
HCV coinfection should be eradicated in all HIV infected individuals for the following reasons:
- High mortality due to hepatocellular carcinoma and unbalanced cirrhosis deriving from a rapid progression of the 
hepatic disease (Ioannou et al. 2013).
- Negative impact of the HCV infection on:
a) Kidney function (Ioannou et al. 2013) and, in general, on mortality not associated to hepatic disease (Grint et al. 
2014);
b) Increase of CD4 T cell count during cART (Potter et al. 2010).
- Possible negative impact of HCV on:
a) HIV disease progression even in presence of cART (De Luca et al. 2002);
b) Osteoporosis (Lo Re et al. 2012);
c) Cardiovascular disease (Butt et al. 2014);
d) Onset of diabetes (Howard et al. 2010).
HCV eradication is associated with a decreased incidence of hepatic failure and mortality mainly in patients with 
advanced liver disease (Berenguer et al. 2012), but also in patients with moderate fibrosis (Berenguer et al. 2014).
Rate of 
recommendation
Clinical conditions
Maximum [AI] Patients with unbalanced liver disease or hepatocellular carcinoma who are eligible for liver 
transplant
Patients who underwent solid organ transplantation (liver or other organs)
Patients with hepatic cirrhosis or advanced fibrosis (histology: >F2 METAVIR or S3 ISHAK 
and/or Stiffness >10 as determined by fibroscan and/or con FIB4 >3.25)§
Patients with cryoglobulinemia and symptomatic vasculitis.
Patients with nephrotic syndrome or membranoproliferative glomerulonephritis non HIV 
associated
Very high [AII] Patients with moderate fibrosis (histology: >F1 METAVIR o S2 ISHAK and/or Stiffness >7.1 
as determined by fibroscan and/or FIB4 >1.45) (Berenguer et al. 2014)
High [AII] All remaining patients co-infected with HIV/HCV (Grint et al. 2014)
§There are no evidences of increased survival after HCV eradication in patients suffering from unbalanced cirrhosis or hepatocellular carci-
noma. The choice of whether or not to treat a patients must be evaluated for each case separately and the therapy must be managed together 
with liver failure specialists (European Association for the Study of the Liver 2014).
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TABLE 13 - HCV therapy guidelines for HIV/HCV co-infected patients (HCV genotype 1, 5, 6) 
Stage of 
the disease§
Response to 
previous PR 
therapy#
PRa PRa 
BOCc
PRa SIM PRa
DCV
PRa SOF SOFO
R
SOF
SIM +Rg
SOF
DCV 
+Rg
SOF
LDV
+Rg
3D + Rg
Non 
cirrhosis
Never treated
Relapsing
B-I in RVRb/
Not 
recommended
B-I in HCV 
G1bA-II se 
RVRbcef
Not 
recommended
A-II/B-IId B-I A-IIl A-II A-II A-II
Not responding Not 
recommended
Not recommended C-IId Not 
recommended
A-II/B-II in
PI experienced 
anti HCV
A-III A-II A-II
Cirrhosis Never treated
Relapsing
Not 
recommended
Not recommended B-II in HCV G1a
C-III in HCV 
G1bd
C-III B-IIl A-IV A-II A-II
Not responding Not 
recommended
Not recommended C-II Not 
recommended
B-II / C-II in
PI experienced 
anti HCVl
A-IV A-II A-II
Unbalanced 
Cirrhosis
Contraindicated Contraindicated Contraindicated Contraindicated C-III Not 
recommended 
in patients with 
hepatocellular 
liver failure
A-IV B-II Not 
recommended
TABLE 14 - HCV therapy guidelines for HIV/HCV co-infected patients (HCV genotype 2).
Stage of disease§ Response to previous PEG IFN + RBV 
therapy#
PRa PRa+ SOFg SOF + R 
(12-24 weeks)
Non Cirrhosis Never treated/Relapsing C-I; B-I se RVRb A-IV A-II
Not responding Not recommended B-IV B-II
Cirrhosis Never treated/Relapsing C-I ; B-I se RVRb A-IV B-II
Not responding
Not recommended
B-IV C-III
Unbalanced Cirrhosis* Not recommended C-IV
Legend Table 13-16: Only few data are available concerning the efficacy against genotype 5 and 6, generally their response is considered 
similar to the one of HCV genotype 1 viruses. § Stage of the disease: Cirrhosis (Stiffness >12 and or histological staging F4 METAVIR or 
S4-5 Ishak). #Previous therapy: Naïve: patients who never used PR. Experienced (Exp) patients who were treated using PR. 
Relapsing (Rel): patients with HCV RNA below the detection limit at the end of PR treatment cycle who relapsed afterwards. Non re-
sponders (NR): patients with detectable HIV RNA after PR treated (HCV RNA decrease lower than 2Log10 after 12 weeks). *Class B or C 
decompensated cirrhosis according to Child Turcotte Pugh classification. aPegylated interferon is contraindicated in subjects intolerant 
to interferon in previous therapies and/or serum albumine <3.5 g/dL with PLT <100.000 and/or other contraindication as reported in 
the Summary of Product Characteristics (SCP). bRVR: HCVRNA <25 IU/ml after 4 weeks of therapy in combination with PR or with PR 
+ Boceprevir. cPR + BOC or SIM Response Guided Therapy: see SCP. dPR + SOF: B in HCV G1 a naive C in HCV G1b and experienced 
patients. ePR + SIM: Not recommended in HCV G1a harbouring the Q80K polymorphism. fPR + DCV Not recommended in HCV G1a. 
gTherapy indications for ribavirine are reported in the SCP.
hTreatments with SOF e DCV without ribavirine for 12 weeks has shown SVR <70% in cirrhotic HCV G3 experienced e naïve patients. 
Longer therapy (24 weeks) or combination with ribavirine (12 weeks) will likely increase SVR. iIn a pilot study evaluating SOF e LDV 
without ribavirine for 12 weeks SVR was 89% in 28 non cirrhotic experienced patients and 73% in cirrhotic experienced patients. lAvai-
lable data concerning SIM + SOF are mainly deriving from retrospective analysis of longitudinal cohorts or public available database. 
Predictive factors for failure are: hepatic cirrhosis (stronger effect if advanced), low albumin levels (albumin <3.5 g/dl o PLT <75.000/
mm3 o previous hepatic disease), infection with HCV genotype G1a and previous failure to triple therapy with PR + BOC or TEL. mTre-
atment with SIM is not indicated in class CTP, B or C decompensated hepatic cirrhosis. SIM is a therapeutic option, if no other drug is 
available, for treatment of class B decompensated hepatic cirrhosis with controlled ascites if indices of liver function (indirect bilirubin, 
serum albumin, INR) are within the normal range.
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TABLE 15 - HCV therapy guidelines for HIV/HCV co-infected patients (HCV genotype 3).
Stage of disease§ Response to previous 
PEG IFN + RBV therapy#
PRa PRa + SOF SOF + R 
(24 weeks)
DCV + SOF 
± Rgh
SOF LDV 
FDCgi
Non Cirrhosis Never treated/Relapsing C-I/ B-I if RVRb A-IV A-II A-III 
(12 weeks)
A-IV
Not responding Not recommended B-IV A-II A-III (12 weeks no R) B-IV
Cirrhosis Never treated/Relapsing C-I/B-I se RVRb Data not 
available
A-IV C-IV (12 weeks) A-IV
Not responding Not recommended B-IV C-III C-III (12 weeks no R) C-IV
Unbalanced Cirrhosis Not recommended C-IV B-IV C-IV
TABLE 16 - HCV therapy guidelines for HIV/HCV co-infected patients (HCV genotype 4).
Stage of 
disease§
Response to 
previous PEG 
IFN + RBV 
therapy#
PRa PRa + 
SOF
PRa + 
SIMc
PRa + 
DCVc
SOF 
+ R 
(24 weeks)
SOF-SIM + R DCV 
+ SOF 
+ Rg
SOFLDV 
FDC+Rg
Ombitasvir/ 
Paritaprevir/
Ritonavir FDCg
Non 
Cirrhosis
Never treated/
Relapsing
BI in RVRb A-III B-III B-III A-III A-IV A-IV A-IV A-III
Not responding Not 
recommended
Data not 
available 
C-III Data not 
available
A-III A-IV A-IV A-IV A-III
Cirrhosis Never treated/
Relapsing
Not 
recommended
A-IV C-IV B-.IV A-IV A-IV A-IV A-IV Data not 
available
Not responding Not 
recommended
Data not 
available
C-IV Data not 
available
B-IV A-IV A-IV A-IV Data not 
available
Unbalanced 
Cirrhosis*
Not 
recommended
Not 
recommended
Not 
recommended
Not 
recommended
Not 
recommended
B-IV Not recommended 
in patients with 
hepatocellular liver 
failurem 
A-IV A-IV Not 
recommended
TABLE 17 - Rating scheme for degree of recommendation (A) and level of evidence 
(B) in HIV/HCV coinfected patients.
Degree of recommendation
Cumulative efficacy A >90%.
B 80-90%.
C <80%.
Not recommended Not recommended if alternative treatments are available
Data not available Limited clinical data available
Level of evidence I Data from >100 HIV infected patients.
II Data from >100 HIV infected and uninfected patients
III Dati from <100 HIV infected and uninfected patients 
IV Anecdotical data
List of abbrevations
3D: ritonavir-boosted paritaprevir, plus ombi-
tasvir and dasabuvir (Abbvie); 3TC: lamividu-
ine; ABC: abacavir; ATV/r: ritonavir boosted 
atazanavir; ARV: antiretroviral drugs; BD: twice 
a day (bis in die); BMD: bone mineral density; 
BOC: Boceprevir; cART: combined antiretrovi-
ral therapy; COBI: cobicistat; CRCL: creatinine 
clearance; CSF: cerebrospinal fluid; DCV: Da-
clatasvir; DTG: dolutegravir; DRV/r: ritonavir 
boosted darunavir; EFV: efavirenz; EVG: el-
vitegravir; FDC: fixed dose combinations; FTC: 
emitricitabine; GFR: glomerular filtration rate; 
INI: integrase inhibitors; LDV: Ledipasvir; LDR: 
Less Drug Regimen; LPV/r: ritonavir boosted 
lopinavir NRTI: nucleoside reverse transcrip-
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tase inhibitor; HSR: hypersensitivity reactions; 
NRTI: Non-Nucleoside Reverse Transcriptase 
Inhibitor; N(t)RTs: nucleoside/nucleotide re-
verse transcriptase inhibitors; NVP: nevirapine; 
PR Pegylated Interferon + Ribavirine; PI/r: ri-
tonavir boosted protease inhibitor; QD: once a 
day (quaque die); R: Ribavirine; RAL:raltegravir; 
RCT: randomized clinical trials; RPV: rilpivirine; 
RTV: ritonavir; SIME: simeprevir; SOF: sofosbu-
vir; STR: single tablet regimens; SVR: sustained 
virological response; TDF: tenofovir disoproxil 
fumarate.
ACKNOWLEDGMENTS
Institutional referees: Ensoli Barbara Istituto 
Superiore di Sanità - CNAIDS, Rome; Moroni 
Mauro Università degli Studi di Milano, Milan.
Coordinator: Lazzarin Adriano, Università Vi-
ta-Salute San Raffaele, Milan.
Executive commitee: Andreoni Massimo, Uni-
versità degli Studi di Roma Tor Vergata, Roma; 
Antinori Andrea, Istituto Nazionale Malattie 
Infettive L. Spallanzani, Roma; Guerra Ranieri, 
Ministero della Salute, Roma; Ippolito Giuseppe, 
Istituto Nazionale Malattie Infettive L. Spallanza-
ni, Roma; Marcotullio Simone, Istituto Superio-
re di Sanità - CNAIDS; Nadir Onlus, Roma; Palù 
Giorgio, Università degli Studi di Padova, Pa-
dova; Pani Luca, Agenzia Italiana del Farmaco, 
Roma; Pompa Maria Grazia, Ministero della Sa-
lute, Roma; Ricciardi Walter, Istituto Superiore 
di Sanità, Roma; Vella Stefano, Istituto Superio-
re di Sanità - Dipartimento del Farmaco, Roma.
Editorial coordinators: Antinori Andrea, Istituto 
Nazionale Malattie Infettive L. Spallanzani, Roma; 
Marcotullio Simone, Istituto Superiore di Sanità - 
Centro Nazionale AIDS; Nadir Onlus, Roma.
Italian HIV Guidelines Working Group: Am-
massari Adriana, Istituto Nazionale Malattie 
Infettive L. Spallanzani, Roma; Angarano Gioac-
chino, Università degli Studi di Bari; Armignacco 
Orlando, Ospedale Belcolle, Viterbo; Babudieri 
Sergio, Università degli Studi di Sassari; Bini 
Teresa, Azienda Ospedaliera - Polo Universitar-
io San Paolo, Milano; Bonfanti Paolo, Azienda 
Ospedaliera della Provincia di Lecco; Bonora 
Stefano, Università degli Studi di Torino; Bor-
deri Marco, Azienda Ospedaliera Sant’Orsola 
Malpighi, Bologna; Breveglieri Michele, Arcigay, 
Verona; Bruno Raffaele, Policlinico San Matteo, 
Pavia; Capobianchi Maria Rosaria, Istituto Na-
zionale Malattie Infettive L. Spallanzani, Roma; 
Cagarelli Roberto, Regione Emilia-Romagna, 
Sanità Pubblica, Bologna; Calcagno Andrea, Uni-
versità degli Studi di Torino, Torino; Castagna 
Antonella, Ospedale San Raffaele, Milano; Cas-
telli Francesco, Università degli Studi di Brescia; 
Cattelan Anna Maria, Ospedale Santa Maria della 
Misericordia, Rovigo; Cauda Roberto, Università 
Cattolica del Sacro Cuore, Roma; Cerioli Alessan-
dra, Lega Italiana per la Lotta contro l’AIDS, Bo-
logna; Chirianni Antonio, Azienda Ospedaliera D. 
Cotugno, Napoli; Cingolani Antonella, Università 
Cattolica del Sacro Cuore, Roma; Cinque Paola, 
Ospedale San Raffaele, Milano; Corbelli Giulio 
Maria, Plus Onlus, Bologna; d’Arminio Monforte 
Antonella, Università degli Studi di Milano; d’Et-
torre Gabriella, Università degli Studi di Roma La 
Sapienza, Roma; De Carli Gabriella, Istituto Na-
zionale Malattie Infettive L. Spallanzani, Roma; 
De Luca Andrea, Azienda Ospedaliera Universi-
taria, Siena; Università Cattolica del Sacro Cuore, 
Roma; Di Biagio Antonio, Azienda Ospedaliera 
San Martino, Genova; Di Perri Giovanni, Uni-
versità degli Studi di Torino; Di Pietro Massimo, 
Azienda Sanitaria di Firenze; El Hamad Issa, 
Azienda Ospedaliera Spedali Civili, Brescia; Erri-
co Margherita, NPS Italia Onlus, Napoli; Finarel-
li Alba Carola, Regione Emilia-Romagna, Sanità 
Pubblica, Bologna; Gaeta Giovanni Battista, II 
Università di Napoli; Gervasoni Cristina, Azien-
da Ospedaliera L. Sacco, Milano; Galli Massimo, 
Università degli Studi di Milano; Giacomet Vania, 
Azienda Ospedaliera L. Sacco, Milano; Gianotti 
Nicola, Ospedale San Raffaele, Milano Giaquin-
to Carlo, Azienda Ospedaliera di Padova; Girardi 
Enrico, Istituto Nazionale Malattie Infettive L. 
Spallanzani, Roma; Gori Andrea, Ospedale San 
Gerardo, Università di Milano-Bicocca, Monza; 
Grossi Paolo, Università degli Studi dell’Insub-
ria, Varese; Guaraldi Giovanni, Università de-
gli Studi di Modena e Reggio Emilia, Modena; 
Ivanovic Jelena, Agenzia Italiana del Farmaco, 
Roma; Lichtner Miriam, Sapienza Università di 
Roma Polo Pontino, Roma; Liuzzi Giuseppina, 
Istituto Nazionale Malattie Infettive L. Spallan-
zani, Roma; Lo Caputo Sergio, Azienda Sanitar-
ia di Firenze; Maggi Paolo, Policlinico di Bari; 
Maggiolo Franco, Ospedali Riuniti di Bergamo; 
Malena Marina, Centro di Medicina Comunitar-
ia ULSS 20, Verona; Marchetti Giulia, Università 
degli Studi di Milano, Milano; Maserati Renato, 
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2014 319
Policlinico San Matteo, Pavia; Mastroianni Clau-
dio, Università degli Studi di Roma La Sapienza, 
Roma; Matteelli Alberto, Università degli Studi di 
Brescia; Mazzotta Francesco, Azienda Sanitaria 
di Firenze; Mussini Cristina, Università degli Stu-
di di Modena e Reggio Emilia, Modena; Nicastri 
Emanuele, Istituto Nazionale di Malattie Infettive 
L. Spallanzani, Roma; Nozza Silvia,  Ospedale 
San Raffaele, Milano; Oldrini Massimo, Lega Ital-
iana per la Lotta contro l’AIDS, Milano; Pascucci 
Maria Grazia, Regione Emilia-Romagna, Sanità 
Pubblica, Bologna; Perno Carlo-Federico, Univer-
sità degli Studi di Roma Tor Vergata, Roma; Pres-
tileo Tullio, Ospedale Civico-Benfratelli, Palermo; 
Puoti Massimo, Azienda Ospedaliera Ospedale 
Niguarda Ca’ Granda, Milano; Puro Vincenzo, Is-
tituto Nazionale Malattie Infettive L. Spallanzani, 
Roma; Rancilio Laura, Caritas Italiana, Milano, 
Ravizza Marina, Azienda Ospedaliera, Polo Uni-
versitario San Paolo, Milano; Rizzardini Giulia-
no, Azienda Ospedaliera L. Sacco, Milano; Rus-
coni Stefano, Università degli Studi di Milano; 
Santoro Maria, Università degli Studi di Roma 
Tor Vergata, Roma; Sighinolfi Laura, Azien-
da-Ospedaliero Universitaria di Ferrara; Stagnitta 
Maria, Coordinamento Nazionale delle Comunità 
di Accoglienza, Firenze; Starnini Giulio, Ospedale 
Belcolle di Viterbo; Tamburrini Enrica, Univer-
sità Cattolica del Sacro Cuore, Roma; Tambussi 
Giuseppe, Ospedale San Raffaele, Milano; Tav-
io Marcello, Azienda Ospedaliero-Universitaria 
Ospedali Riuniti di Ancona; Torti Carlo, Univer-
sità Magna Graecia, Catanzaro; Vaccher Emanu-
ela, Centro di Riferimento Oncologico di Aviano; 
Viscoli Claudio, Università di Genova; Visintini 
Raffaele, Ospedale San Raffaele, Milano; Vullo 
Vincenzo, Università degli Studi di Roma La Sa-
pienza, Roma; Zaccarelli Mauro, Istituto Nazio-
nale di Malattie Infettive L. Spallanzani, Roma; 
Zuccotti Gian Vincenzo, Università degli Studi di 
Milano.
Special Acknowledgments: Caraglia Anna, 
Ministero della Salute, Roma; Monarca Rober-
to, Ospedale Belcolle di Viterbo, Viterbo.
REFERENCES
allaveNa c., Dailly e., reliquet v., boNNet b., PiN-
eau S., et al. (2014). Switching from tenofovir/
emtricitabine and nevirapine to a tenofovir/em-
tricitabine/rilpivirine single-tablet regimen in vi-
rologically suppressed, HIV-1-infected subjects. 
J. Antimicrob. Chemother. 69, 2804-2808.
aNaNworaNich J., Schuetz a., vaNDergeeteN c., Sereti 
i., De Souza M., et al. (2012). Impact of multi-tar-
geted antiretroviral treatment on gut T cell deple-
tion and HIV reservoir seeding during acute HIV 
infection. PLoS One. 7, e33948.
aNtiNori a., arribaS J., Fehr J., girarD P.M., horbaN 
a., et al. (2014). The PROTEA trial: darunavir/
ritonavir with or without nucleoside analogues, 
for patients with HIV-1 RNA below 50 copies/mL. 
J. Int. AIDS Soc. 17 (Suppl. 3), 19525.
arribaS J.r., cluMeck N., NelSoN M., hill a., vaN 
DelFt y., et al. (2012). The MONET trial: week 
144 analysis of the efficacy of darunavir/ritona-
vir (DRV/r) monotherapy versus DRV/r plus two 
nucleoside reverse transcriptase inhibitors, for 
patients with viral load <50 HIV-1 RNA copies/
mL at baseline. HIV Med. 13, 398-405.
arribaS Jr, r DelgaDo, a arraNz, r MuNoz, J Por-
tilla, et al. (2009). “Lopinavir-ritonavir mono-
therapy versus lopinavir-ritonavir and 2 nucleo-
sides for maintenance therapy of HIV: 96-week 
analysis. J. Acquir. Immune Defic. Syndr. 51, 
147-152.
arribaS J.r., Pialoux g., gathe J., Di Perri g., reyNeS 
J., et al. (2014). Simplification to coformulated 
elvitegravir, cobicistat, emtricitabine, and teno-
fovir versus continuation of ritonavir-boosted 
protease inhibitor with emtricitabine and teno-
fovir in adults with virologically suppressed HIV 
(STRATEGY-PI): 48 week results of a randomised, 
open-label, phase 3b, non-inferiority trial. Lancet 
Infect. Dis. 14, 581-589.
arribaS J.r., PozNiak a.l., gallaNt J.e., DeJeSuS e., 
gazzarD b., et al. (2008). Tenofovir disoproxil fu-
marate, emtricitabine, and efavirenz compared 
with zidovudine/lamivudine and efavirenz in 
treatment-naive patients: 144-week analysis. J. 
Acquir. Immune Defic. Syndr. 47, 74-78.
Association for the Study of Liver Diseases (AASLD) 
aND iNterNatioNal aNtiviral Society - USA (IAS-
USA). Recommendations for Testing, Manag-
ing, and Treating Hepatitis C. from http://www.
hcvguidelines.org/.
attia S., egger M., Muller M., zwahleN M., low N. 
(2009). Sexual transmission of HIV according to 
viral load and antiretroviral therapy: systematic 
review and meta-analysis. Aids. 23, 1397-1404.
baDri M., bekker l.g., orrell c., Pitt J., cillierS F., 
et al. (2004). Initiating highly active antiretrovi-
ral therapy in sub-Saharan Africa: an assessment 
of the revised World Health Organization scal-
ing-up guidelines. Aids. 18, 1159-1168.
baxi S.M., greeNblatt r.M., bacchetti P., Scherzer 
r., MiNkoFF h., et al. (2014). Common clinical 
conditions - age, low BMI, ritonavir use, mild 
renal impairment - affect tenofovir pharmacoki-
A. Antinori et al.320
netics in a large cohort of HIV-infected women. 
Aids. 28, 59-66.
bereNguer J., roDriguez e., MiralleS P., voN wich-
MaNN M.a., loPez-alDeguer J., et al. (2012). Sus-
tained virological response to interferon plus rib-
avirin reduces non-liver-related mortality in pa-
tients coinfected with HIV and Hepatitis C virus. 
Clin. Infect. Dis. 55, 728-736.
bereNguer J., zaMora F.x., carrero a., voN wich-
MaNN M.a., creSPo M., et al. (2014). Effects of 
sustained viral response in patients with HIV and 
chronic hepatitis C and nonadvanced liver fibro-
sis. J. Acquir. Immune Defic. Syndr. 66, 280-287.
bierMaN w.F., vaN agtMael M.a., NiJhuiS M., DaNNer 
S.a., boucher c.a. (2009). HIV monotherapy 
with ritonavir-boosted protease inhibitors: a sys-
tematic review. Aids. 23, 279-291.
borghetti a., FabbiaNi M., Piccoli b., MoNDi a., D’avi-
No a., et al. (2014). Simplification therapy with 
lamivudine and boosted darunavir in a cohort 
of treatment-experienced HIV-infected patients. 
Italian Conference on AIDS and Retroviruses 
(ICAR), Rome, Italy.
breNNaN a., browNe J.P., horgaN M. (2014). A sys-
tematic review of health service interventions to 
improve linkage with or retention in HIV care. 
AIDS. Care 26, 804-812.
breNNer b.g., roger, J.P. routy M., MoiSi D., 
NteMgwa M., et al. (2007). High rates of forward 
transmission events after acute/early HIV-1 infec-
tion. J. Infect. Dis. 195, 951-959.
browN t.t., MoSer c., currier J.S., ribauDo h., 
rotheNberg J., et al. (2014). Bone density chang-
es after antiretroviral initiation with protease in-
hibitors or raltegravir 21st Conference on Retrovi-
ruses and Opportunistic Infections Boston, MA.
butt a.a., chew k.w., currier J., corey k., chuNg 
r. et al. (2014). Hepatitis C (HCV) viremia and 
the risk of acute myocardial infarction at various 
lipid levels. 21st Conference on Retroviruses and 
Opportunistic Infections (CROI) Boston, MA.
cahN P., aNDraDe-villaNueva J., arribaS J.r., gatell 
J.M., laMa J.r., et al. (2014). Dual therapy with 
lopinavir and ritonavir plus lamivudine versus 
triple therapy with lopinavir and ritonavir plus 
two nucleoside reverse transcriptase inhibitors 
in antiretroviral-therapy-naive adults with HIV-
1 infection: 48 week results of the randomised, 
open label, non-inferiority GARDEL trial. Lancet 
Infect. Dis. 14, 572-580.
caiN le, a. PhilliPS, S. loDi, c. SabiN, l. baNSi, et 
al. (2012). The effect of efavirenz versus nevi-
rapine-containing regimens on immunologic, 
virologic and clinical outcomes in a prospective 
observational study. Aids. 26, 1691-1705.
caMeroN D.w., Da Silva b.a., arribaS J.r., MyerS r.a., 
belloS N.c., et al. (2008). A 96-week comparison 
of lopinavir-ritonavir combination therapy fol-
lowed by lopinavir-ritonavir monotherapy versus 
efavirenz combination therapy. J. Infect. Dis. 198, 
234-240.
carey D. (2014). Efavirenz 400 mg daily remains 
non-inferior to 600 mg: 96 week data from the 
double-blind, placebo-controlled ENCORE1 
study. J. Int. AIDS Soc. 17 (Suppl. 3), 19523.
clotet b., FeiNberg J., vaN luNzeN J., khuoNg-JoSS-
eS M.a., aNtiNori a., et al. (2014). Once-daily 
dolutegravir versus darunavir plus ritonavir in 
antiretroviral-naive adults with HIV-1 infection 
(FLAMINGO): 48 week results from the ran-
domised open-label phase 3b study. Lancet. 383, 
2222-2231.
cluMeck N., MoliNa J.M., heNry k., gathe J., rock-
Stroh J.k., et al. (2014). A randomized, dou-
ble-blind comparison of single-tablet regimen 
elvitegravir/cobicistat/emtricitabine/tenofovir 
DF vs ritonavir-boosted atazanavir plus emtricit-
abine/tenofovir DF for initial treatment of HIV-1 
infection: analysis of week 144 results. J. Acquir. 
Immune Defic. Syndr. 65, e121-124.
coheN c., wohl D., arribaS J., heNry k., bloch M., 
et al. (2013a). STaR Study: single-tablet regimen 
rilpivirine/emtricitabine/tenofovir df has non-in-
ferior efficacy compared to efavirenz/emtricit-
abine/tenofovir df and improves patient reported 
outcomes. 7th IAS Conference on HIV Pathogen-
esis, Treatment, and Prevention, Kuala Lumpur, 
Malaysia.
coheN c., wohl D., arribaS J., heNry k., vaN luNzeN 
J., et al. (2013b). Single-tablet regimen rilpivir-
ine/emtricitabine/tenofovir df maintains non-in-
feriority to efavirenz/emtricitabine/ tenofovir DF 
in ART-naïve adults week 96 results. 14th Europe-
an AIDS Conference, Brussels, Belgium.
coheN c., wohl D., arribaS J.r., heNry k., vaN 
luNzeN J., et al. (2014). Week 48 results from a 
randomized clinical trial of rilpivirine/emtricit-
abine/tenofovir disoproxil fumarate vs. efavirenz/
emtricitabine/tenofovir disoproxil fumarate in 
treatment-naive HIV-1-infected adults. Aids. 28, 
989-997.
coheN c.J., aNDraDe-villaNueva J., clotet b., Fourie 
J., JohNSoN M.a., et al. (2011a). Rilpivirine ver-
sus efavirenz with two background nucleoside 
or nucleotide reverse transcriptase inhibitors 
in treatment-naive adults infected with HIV-1 
(THRIVE): a phase 3, randomised, non-inferiori-
ty trial. Lancet. 378, 229-237.
coheN c.J., MoliNa J.M., cahN P., clotet b., Fourie 
J., et al. (2012). Efficacy and safety of rilpivirine 
(TMC278) versus efavirenz at 48 weeks in treat-
ment-naive HIV-1-infected patients: pooled re-
sults from the phase 3 double-blind randomized 
ECHO and THRIVE Trials. J. Acquir. Immune 
Defic. Syndr. 60, 33-42.
coheN c.J., MoliNa J.M., caSSetti i., chetchotiSakD 
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2014 321
P., lazzariN a., et al. (2013c). Week 96 efficacy 
and safety of rilpivirine in treatment-naive, HIV-1 
patients in two Phase III randomized trials. Aids. 
27, 939-950.
coheN M.S., cheN y.q., Mccauley M., gaMble t., 
hoSSeiNiPour M.c., et al. (2011b). Prevention of 
HIV-1 infection with early antiretroviral therapy. 
N. Engl. J. Med. 365, 493-505.
collaboratioN h.-c., caiN l.e., logaN r., robiNS 
J.M., SterNe J.a., et al. (2011). When to initiate 
combined antiretroviral therapy to reduce mor-
tality and AIDS-defining illness in HIV-infected 
persons in developed countries: an observational 
study. Ann. Intern. Med. 154, 509-515.
collaboratioN h.-c., ray M., logaN r., SterNe J.a., 
herNaNDez-Diaz S., et al. (2010). The effect of com-
bined antiretroviral therapy on the overall mortal-
ity of HIV-infected individuals. Aids. 24, 123-137.
collaboratioN oF obServatioNal, hivereie, lewDeN 
c., boutelouP v., De wit S., SabiN c., et al. (2012). 
All-cause mortality in treated HIV-infected adults 
with CD4 >/=500/mm3 compared with the general 
population: evidence from a large European ob-
servational cohort collaboration. Int. J. Epidemi-
ol. 41, 433-445.
cozzi lePri a., PhilliPS a.N., D’arMiNio MoNForte 
a., caStelli F., aNtiNori a., et al. (2001). When 
to start highly active antiretroviral therapy in 
chronically HIV-infected patients: evidence from 
the ICONA study. Aids. 15, 983-990.
crawForD t.N. (2014). Poor retention in care one-
year after viral suppression: a significant predic-
tor of viral rebound. AIDS Care. 26, 1393-1399.
crawForD t.N., SaNDerSoN w.t., breheNy P., FleMiNg 
S.t., thorNtoN a. (2014). Impact of non-HIV re-
lated comorbidities on retention in HIV medical 
care: does retention improve over time? AIDS Be-
hav. 18, 617-624.
curraN a., MartiNez e., SauMoy M., Del rio l., creSPo 
M., et al. (2012). Body composition changes after 
switching from protease inhibitors to raltegravir: 
SPIRAL-LIP substudy. Aids. 26, 475-481.
cySique l.a., vaiDa F., leteNDre S., gibSoN S., cherNer 
M., et al. (2009). Dynamics of cognitive change in 
impaired HIV-positive patients initiating antiret-
roviral therapy. Neurology. 73, 342-348.
D’arMiNio MoNForte a., giaNotti N., cozzi-lePri a., 
PiNNetti c., aNDreoNi M., et al. (2014). Durability 
of lopinavir/ritonavir monotherapy in individuals 
with viral load </=50 copies/ml in an observation-
al setting. Antivir. Ther. 19, 319-324.
Daar e.S., Pilcher c.D., hecht F.M. (2008). Clinical 
presentation and diagnosis of primary HIV-1 in-
fection. Curr. Opin. HIV AIDS. 3, 10-15.
Daar e.S., tierNey c., FiSchl M.a., Sax P.e., MollaN 
k., et al. (2011). Atazanavir plus ritonavir or efa-
virenz as part of a 3-drug regimen for initial treat-
ment of HIV-1. Ann. Intern. Med. 154, 445-456.
De luca a., bugariNi r., lePri a.c., Puoti M., girarDi 
e., et al. (2002). Coinfection with hepatitis virus-
es and outcome of initial antiretroviral regimens 
in previously naive HIV-infected subjects. Arch. 
Intern. Med. 162, 2125-2132.
DeJeSuS e., herrera g., teoFilo e., gerStoFt J., bu-
eNDia c.b., et al. (2004). Abacavir versus zidovu-
dine combined with lamivudine and efavirenz, 
for the treatment of antiretroviral-naive HIV-in-
fected adults. Clin. Infect. Dis. 39, 1038-1046.
DeJeSuS e., rockStroh J.k., heNry k., MoliNa J.M., 
gathe J., et al. (2012). Co-formulated elvitegravir, 
cobicistat, emtricitabine, and tenofovir disoprox-
il fumarate versus ritonavir-boosted atazanavir 
plus co-formulated emtricitabine and tenofovir 
disoproxil fumarate for initial treatment of HIV-
1 infection: a randomised, double-blind, phase 3, 
non-inferiority trial. Lancet. 379, 2429-2438.
DeJeSuS e., youNg b., MoraleS-raMirez J.o., SloaN 
l., warD D.J., et al. (2009). Simplification of 
antiretroviral therapy to a single-tablet regimen 
consisting of efavirenz, emtricitabine, and teno-
fovir disoproxil fumarate versus unmodified an-
tiretroviral therapy in virologically suppressed 
HIV-1-infected patients. J. Acquir. Immune Defic. 
Syndr. 51, 163-174.
Di giaMbeNeDetto S., FabbiaNi M., colaFigli M., cic-
carelli N., FariNa S., et al. (2013). Safety and fea-
sibility of treatment simplification to atazanavir/
ritonavir + lamivudine in HIV-infected patients 
on stable treatment with two nucleos(t)ide re-
verse transcriptase inhibitors + atazanavir/ritona-
vir with virological suppression (Atazanavir and 
Lamivudine for treatment Simplification, AtLaS 
pilot study). J. Antimicrob. Chemother. 68, 1364-
1372.
DiNg x., aNDraca-carrera e., cooPer c., Miele P., 
korNegay c., et al. (2012). No association of aba-
cavir use with myocardial infarction: findings of 
an FDA meta-analysis. J. Acquir. Immune Defic. 
Syndr. 61, 441-447.
DoNNell D., baeteN J.M., kiarie J., thoMaS k.k., et 
al. (2010). Heterosexual HIV-1 transmission after 
initiation of antiretroviral therapy: a prospective 
cohort analysis. Lancet. 375, 2092-2098.
eroN J.J. Jr., rockStroh J.k., reyNeS J., aNDraDe-vil-
laNueva J., raMalho-MaDruga J.v., et al. (2011). 
Raltegravir once daily or twice daily in previous-
ly untreated patients with HIV-1: a randomised, 
active-controlled, phase 3 non-inferiority trial. 
Lancet Infect. Dis. 11, 907-915.
eroN J.J., youNg b., cooPer D.a., youle M., DeJeSuS 
e., et al. (2010). Switch to a raltegravir-based reg-
imen versus continuation of a lopinavir-ritona-
vir-based regimen in stable HIV-infected patients 
with suppressed viraemia (SWITCHMRK 1 and 
2): two multicentre, double-blind, randomised 
controlled trials. Lancet. 375, 396-407.
A. Antinori et al.322
eStrella M., FiNe D.M., gallaNt J.e., rahMaN M.h., 
NagaJothi N., et al. (2006). HIV type 1 RNA lev-
el as a clinical indicator of renal pathology in 
HIV-infected patients. Clin. Infect. Dis. 43, 377-
380.
euroPeaN aiDS cliNical Society (EACS). (2014). No-
vember 2014). EACS Treatment Guidelines Ver-
sion 7.1.” from http://www.eacsociety.org/files/
guidelines_english_71_141204.pdf.
euroPeaN aSSociatioN For the StuDy oF the liver. 
(2014). EASL Recommendations on Treatment of 
Hepatitis C. from http://files.easl.eu/easl-recom-
mendations-on-treatment-of-hepatitis-C.pdf.
euroPeaN MeDiciNeS ageNcy. (2013). Europe-
an public assessment report (EPAR) - Ty-
bost (Cobicistat) SUMMARY OF PROD-
UCT CHARACTERISTICS. from http://
www.ema.europa.eu/docs/en_GB/document 
_library/EPAR_-_Product_Information/human/ 
002572/WC500153014.pdf.
FiDler S., oxeNiuS a., braDy M., clarke J., croPley 
i., et al. (2002). Virological and immunological 
effects of short-course antiretroviral therapy in 
primary HIV infection. Aids. 16, 2049-2054.
Ford N., Mofenson L., Shubber Z., Calmy A., An-
drieux-Meyer I., et al. (2014). Safety of efavirenz 
in the first trimester of pregnancy: an updated 
systematic review and meta-analysis. Aids. 28 
(Suppl. 2): S123-131.
gallaNt J.e., DeJeSuS e., arribaS J.r., PozNiak a.l., 
gazzarD b., et al. (2006). Tenofovir DF, emtricit-
abine, and efavirenz vs. zidovudine, lamivudine, 
and efavirenz for HIV. N. Engl. J. Med. 354, 251-
260.
gallaNt J.e., koeNig e., aNDraDe-villaNueva J., che-
tchotiSakD P., DeJeSuS e., et al. (2013). Cobicistat 
versus ritonavir as a pharmacoenhancer of ataza-
navir plus emtricitabine/tenofovir disoproxil fu-
marate in treatment-naive HIV type 1-infected 
patients: week 48 results. J. Infect. Dis. 208, 32-
39.
gallaNt J.e., StaSzewSki S., PozNiak a.l., DeJeSuS e., 
SuleiMaN J.M., et al. (2004). Efficacy and safety 
of tenofovir DF vs stavudine in combination ther-
apy in antiretroviral-naive patients: a 3-year ran-
domized trial. JAMA. 29, 191-201.
garDNer e.M., McleeS M.P., SteiNer J.F., Del rio c., 
burMaN w.J. (2011). The spectrum of engagement 
in HIV care and its relevance to test-and-treat 
strategies for prevention of HIV infection. Clin. 
Infect. Dis. 52, 793-800.
garDNer l.i., giorDaNo t.P., MarkS g., wilSoN t.e., 
craw J.a., et al. (2014). Enhanced personal con-
tact with HIV patients improves retention in pri-
mary care: a randomized trial in 6 US HIV clin-
ics. Clin. Infect. Dis. 59, 725-734.
geretti a.M., arribaS J.r., lathouwerS e., FoSter 
g.M., yakoob r., et al. (2013). Dynamics of cellu-
lar HIV-1 DNA levels over 144 weeks of daruna-
vir/ritonavir monotherapy versus triple therapy 
in the MONET trial. HIV Clin. Trials. 14, 45-50.
gerMaN P., liu h.c., Szwarcberg J., hePNer M., aN-
DrewS J., et al. (2012). Effect of cobicistat on glo-
merular filtration rate in subjects with normal 
and impaired renal function. J. Acquir. Immune 
Defic. Syndr. 61, 32-40.
giaNotti N., Poli a., galli l., MaillarD M., boSSolaS-
co S., et al. (2014a). Dual regimen with daruna-
vir/ritonavir 800/100 mg QD and either lamivu-
dine or emtricitabine as maintenance therapy in 
HIV-infected patients with HIV-RNA <50 copies/
mL. Italian Conference on AIDS and Retrovirus-
es (ICAR), Rome, Italy.
giaNotti N., Poli a., galli M., PaN a., rizzarDiNi g., et 
al. (2014b). Monotherapy with lopinavir/ritonavir 
versus standard of care in HIV-infected patients 
virologically suppressed while on treatment with 
protease inhibitor-based regimens: results from 
the MoLo study. New Microbiol. 37, 439-448.
girarDi e. (2014). Innovative Tools and Methods for 
HIV Prevention. from http://www.icar2014.it/pub-
lic/repository/slide/3111_08.30%20Girardi.pdf.
griJSeN M.l., SteiNgrover r, wit F.w., JurriaaNS S., 
verboN a., et al. (2012). No treatment versus 24 
or 60 weeks of antiretroviral treatment during 
primary HIV infection: the randomized Pri-
mo-SHM trial. PLoS Med. 9, e1001196.
griNSzteJN b., hoSSeiNiPour M.c., ribauDo h.J., SwiN-
DellS S., eroN J., et al. (2014). Effects of early 
versus delayed initiation of antiretroviral treat-
ment on clinical outcomes of HIV-1 infection: 
results from the phase 3 HPTN 052 randomised 
controlled trial. Lancet Infect. Dis. 14, 281-290.
griNt D., PeterS l., rakMaNova a., rockStroh J.k., 
karPov i., et al. (2014). Liver-related death 
among HIV/HCV coinfected individuals, implica-
tions for the era of directly acting antivirals. 21st 
Conference on Retroviruses and Opportunistic 
Infections (CROI), Boston, MA.
grouP DaDS, SabiN c.a., worM S.w., weber r., reiSS 
P., et al. (2008). Use of nucleoside reverse tran-
scriptase inhibitors and risk of myocardial in-
farction in HIV-infected patients enrolled in the 
D:A:D study: a multi-cohort collaboration. Lan-
cet. 371, 1417-1426.
guPta S.k., aNDerSoN a.M., ebrahiMi r., Fralich t., 
grahaM h. et al. (2014). Fanconi syndrome ac-
companied by renal function decline with tenofo-
vir disoproxil fumarate: a prospective, case-con-
trol study of predictors and resolution in HIV-in-
fected patients. PLoS One. 9, e92717.
gutMaNN c., cuSiNi a., guNtharD h.F., Fux c., hirSchel 
b., et al. (2010). Randomized controlled study 
demonstrating failure of LPV/r monotherapy in 
HIV: the role of compartment and CD4-nadir. 
Aids. 24, 2347-2354.
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2014 323
hall h.i., taNg t., weStFall a.o., Mugavero M.J. 
(2013). HIV care visits and time to viral suppres-
sion, 19 U.S. jurisdictions, and implications for 
treatment, prevention and the national HIV/AIDS 
strategy. PLoS One. 8, e84318.
HIV/AIDS Italian Expert Panel. (2014, December 
18, 2014). Linee Guida Italiane sull’utilizzo dei 
farmaci antiretrovirali e sulla gestione diagnos-
tico-clinica delle persone con infezione da HIV-1. 
from http://www.salute.gov.it/imgs/C_17_pubbli-
cazioni_2261_allegato.pdf.
hoFFMaN r.M., black v., techNau k., vaN Der Merwe 
k.J., currier J., et al. (2010). Effects of highly ac-
tive antiretroviral therapy duration and regimen 
on risk for mother-to-child transmission of HIV 
in Johannesburg, South Africa. J. Acquir. Im-
mune Defic. Syndr. 54, 35-41.
hogaN c.M., Degruttola v., SuN x., FiScuS S.a., Del 
rio c., et al. (2012). The setpoint study (ACTG 
A5217): effect of immediate versus deferred an-
tiretroviral therapy on virologic set point in re-
cently HIV-1-infected individuals. J. Infect. Dis. 
205, 87-96.
horberg M.a., hurley l.b., Silverberg M.J., kleiN 
D.b., queSeNberry c.P., et al. (2013). Missed of-
fice visits and risk of mortality among HIV-in-
fected subjects in a large healthcare system in 
the United States. AIDS Patient Care STDS. 27, 
442-449.
howarD a.a., hoover D.r., aNaStoS k., wu x., Shi q., 
et al. (2010). The effects of opiate use and hepa-
titis C virus infection on risk of diabetes mellitus 
in the Women’s Interagency HIV Study. J. Acquir. 
Immune Defic. Syndr. 54, 152-159.
ICONA Foundation - Italian Cohort Naive Antiretrovi-
rals. from http://www.fondazioneicona.org/_new/.
ioaNNou g.N., brySoN c.l., weiSS N.S., Miller r., 
Scott J.D., et al. (2013). The prevalence of cir-
rhosis and hepatocellular carcinoma in patients 
with human immunodeficiency virus infection. 
Hepatology. 57, 249-257.
JoSe S., haMzah l., caMPbell l.J., hill t., FiSher M., 
et al. (2014). Incomplete reversibility of estimat-
ed glomerular filtration rate decline following 
tenofovir disoproxil fumarate exposure. J. Infect. 
Dis. 210, 363-373.
kahN J.o., walker b.D. (1998). Acute human immu-
nodeficiency virus type 1 infection. N. Engl. J. 
Med. 339, 33-39.
karlStroM o., JoSePhSoN F., SoNNerborg a. (2007). 
Early virologic rebound in a pilot trial of ritona-
vir-boosted atazanavir as maintenance monother-
apy. J. Acquir. Immune Defic. Syndr. 44, 417-422.
laNDovitz r.J., ribauDo h.J., oFotokuN i., waNg h., 
baugh b.P., et al. (2014). Efficacy and tolerability 
of atazanavir, raltegravir, or darunavir with FTC/
TDF: ACTG A5257. Conference on Retroviruses 
and Opportunistic Infections, Boston, MA.
lazzaretti c., borghi v., FraNceSchiNi e., guaralDi 
g., MuSSiNi c. (2012). Engagment and retention 
in care of patients diagnosed with HIV infection 
and enrolled in the Modena HIV Surveillance Co-
hort. 11th International Congress on Drug Thera-
py in HIV Infection, Journal of the International 
AIDS Society 2012.
le t., wright e.J., SMith D.M., he w., cataNo g., et 
al. (2013). Enhanced CD4+ T-cell recovery with 
earlier HIV-1 antiretroviral therapy. N. Engl. J. 
Med. 368, 218-230.
lee F.J., aMiN J., bloch M., Pett S.l., Marriott D., 
et al. (2013). Skeletal muscle toxicity associated 
with raltegravir-based combination antiretroviral 
therapy in HIV-infected adults. J. Acquir. Immune 
Defic. Syndr. 62, 525-533.
leNNox J.l., DeJeSuS e., lazzariN a., PollarD r.b., 
MaDruga J.v., et al. (2009). Safety and efficacy of 
raltegravir-based versus efavirenz-based combi-
nation therapy in treatment-naive patients with 
HIV-1 infection: a multicentre, double-blind ran-
domised controlled trial. Lancet. 374, 796-806.
lichteNSteiN k.a., arMoN c., buchacz k., chMiel J.S., 
MoorMaN a.c., et al. (2008). Initiation of antiret-
roviral therapy at CD4 cell counts >/=350 cells/
mm3 does not increase incidence or risk of pe-
ripheral neuropathy, anemia, or renal insufficien-
cy. J. Acquir. Immune Defic. Syndr. 47, 27-35.
lo re v. 3rD, volk J., NewcoMb c.w., yaNg y.x., Free-
MaN c.P., et al. (2012). Risk of hip fracture associ-
ated with hepatitis C virus infection and hepatitis 
C/human immunodeficiency virus coinfection. 
Hepatology. 56, 1688-1698.
lockMaN S., creek t. (2009). Acute maternal HIV 
infection during pregnancy and breast-feeding: 
substantial risk to infants. J. Infect. Dis. 200, 667-
669.
lucero c., torreS b., leoN a., calvo M., leal l., 
et al. (2013). Rate and predictors of non-AIDS 
events in a cohort of HIV-infected patients with a 
CD4 T cell count above 500 cells/mm3. AIDS Res. 
Hum. Retroviruses. 29, 1161-1167.
MaDeDDu g., ruScoNi S., cozzi-lePri a., Di giaMbeN-
eDetto S., boNora S., et al. (2014). Efficacy and 
tolerability of switching to a dual therapy with 
darunavir/r+raltegravir in HIV-infected patients 
with HIV-1 RNA ≤50 cp/mL. Italian Conference 
on AIDS and Retroviruses (ICAR), Rome, Italy.
MaMMoNe a., Navarra a., regiNe v., Pezzotti P., aNge-
letti c., et al. (2014). Prevalence of undiagnosed 
HIV in Italy at the end of 2012: an estimate based 
on surveillance data and disease stage. Italian 
Conference on AIDS and Retroviruses (ICAR), 
Rome, Italy.
MartiNez e., arNaiz J.a., PoDzaMczer D., DalMau D., 
ribera e., et al. (2007). Three-year follow-up of 
protease inhibitor-based regimen simplification 
in HIV-infected patients. Aids. 21, 367-369.
A. Antinori et al.324
MartiNez e., larrouSSe M., llibre J.M., gutierrez 
F., SauMoy M., et al. (2010). Substitution of ral-
tegravir for ritonavir-boosted protease inhibitors 
in HIV-infected patients: the SPIRAL study. Aids. 
24, 1697-1707.
MatthewS g.v., avihiNgSaNoN a., lewiN S.r., aMiN J., 
rerkNiMitr r., et al. (2008). A randomized trial 
of combination hepatitis B therapy in HIV/HBV 
coinfected antiretroviral naive individuals in 
Thailand. Hepatology. 48, 1062-1069.
MccoMSey g., kitch D., Daar e., tierNey c., JaheD 
N., et al. (2010). Bone and limb fat outcomes of 
ACTG A5224s, a substudy of ACTG A5202: a pro-
spective, randomized, partially blinded phase III 
trial of ABC/3TC or TDF/FTC with EFV or ATV/r 
for initial treatment of HIV-1 infection. 17th Con-
ference on Retroviruses and Opportunistic Infec-
tions, San Francisco.
MehaNDru S., PoleS M.a., teNNer-racz k., JeaN-
Pierre P., MaNuelli v., et al. (2006). Lack of mu-
cosal immune reconstitution during prolonged 
treatment of acute and early HIV-1 infection. 
PLoS Med. 3, e484.
MellgreN a., aNtiNori a., ciNque P., Price r.w., 
eggerS c., et al. (2005). Cerebrospinal fluid HIV-
1 infection usually responds well to antiretroviral 
treatment. Antivir. Ther. 10, 701-707.
Merck SharP & DohMe corP. (2015). ISENTRESS 
(FDA approved label - 02/20/2015), from http://
www.accessdata.fda.gov/drugsatfda_docs/label/2
015/022145s035,203045s012,205786s003lbl.pdf.
MillS a.M., aNtiNori a., clotet b., Fourie J., herrera 
g., et al. (2013a). Neurological and psychiatric 
tolerability of rilpivirine (TMC278) vs. efavirenz 
in treatment-naive, HIV-1-infected patients at 48 
weeks. HIV Med. 14, 391-400.
MillS a.M., coheN c., DeJeSuS e., briNSoN c., wil-
liaMS S., et al. (2013b). Efficacy and safety 48 
weeks after switching from efavirenz to rilpivir-
ine using emtricitabine/tenofovir disoproxil fu-
marate-based single-tablet regimens. HIV Clin. 
Trials. 14, 216-223.
MocroFt a., PhilliPS a.N., gatell J., leDergerber b., 
FiSher M., et al. (2007). Normalisation of CD4 
counts in patients with HIV-1 infection and max-
imum virological suppression who are taking 
combination antiretroviral therapy: an observa-
tional cohort study. Lancet. 370, 407-413.
Moh r., DaNel c., MeSSou e., ouaSSa t., gabillarD D., 
et al. (2007). Incidence and determinants of mor-
tality and morbidity following early antiretroviral 
therapy initiation in HIV-infected adults in West 
Africa. Aids. 21, 2483-2491.
MoliNa J.M., aNDraDe-villaNueva J., echevarria 
J., chetchotiSakD P., corral J., et al. (2010). 
Once-daily atazanavir/ritonavir compared with 
twice-daily lopinavir/ritonavir, each in combina-
tion with tenofovir and emtricitabine, for man-
agement of antiretroviral-naive HIV-1-infected 
patients: 96-week efficacy and safety results of 
the CASTLE study. J. Acquir. Immune Defic. Syn-
dr. 53, 323-332.
MoliNa J.M., cahN P., griNSzteJN b., lazzariN a., MillS 
a., et al. (2011). Rilpivirine versus efavirenz with 
tenofovir and emtricitabine in treatment-naive 
adults infected with HIV-1 (ECHO): a phase 3 
randomised double-blind active-controlled trial. 
Lancet. 378, 238-246.
MoliNa J.M., clotet b., vaN luNzeN J., lazzariN a., 
cavaSSiNi M., et al. (2014a). Once-daily dolutegra-
vir is superior to once-daily darunavir/ritonavir 
in treatment-naive HIV-1-positive individuals: 96 
week results from FLAMINGO. J. Int. AIDS Soc. 
17, (Suppl. 3): 19490.
MoliNa J.M., cluMeck N., orkiN c., riMSky l.t., vaN-
veggel S., et al. (2014b). Week 96 analysis of ril-
pivirine or efavirenz in HIV-1-infected patients 
with baseline viral load </=100 000 copies/mL in 
the pooled ECHO and THRIVE phase 3, random-
ized, double-blind trials. HIV Med. 15, 57-62.
MollaN k.r., SMurzyNSki M., eroN J.J., Daar e.S., 
caMPbell t.b., et al. (2014). Association between 
efavirenz as initial therapy for HIV-1 infection 
and increased risk for suicidal ideation or at-
tempted or completed suicide: an analysis of trial 
data. Ann. Intern. Med. 161, 1-10.
MoNtaNer J.S., liMa v.D., harrigaN P.r., loureNco l., 
yiP b., et al. (2014). Expansion of HAART cover-
age is associated with sustained decreases in HIV/
AIDS morbidity, mortality and HIV transmission: 
the “HIV Treatment as Prevention” experience in 
a Canadian setting. PLoS One. 9, e87872.
Mora-PeriS b., watSoN v., vera J.h., weStoN r., 
walDMaN a.D., et al. (2014). Rilpivirine exposure 
in plasma and sanctuary site compartments after 
switching from nevirapine-containing combined 
antiretroviral therapy. J. Antimicrob. Chemother. 
69, 1642-1647.
MwaFoNgo a., NkaNauNeNa k., zheNg y., hogg e., 
SaMaNeka w., et al. (2014). Renal events among 
women treated with tenofovir/emtricitabine in 
combination with either lopinavir/ritonavir or 
nevirapine. Aids. 28, 1135-1142.
Nachega J.b., uthMaN o.a., Del rio c., Mugave-
ro M.J., reeS h., et al. (2014). Addressing the 
Achilles’ heel in the HIV care continuum for the 
success of a test-and-treat strategy to achieve an 
AIDS-free generation. Clin. Infect. Dis. 59 (Suppl. 
1): S21-27.
NaPoli a., couMbiS J., wooD J., Soitkar a., SeekiNS 
D. (2015). Disproportionality analysis of antiret-
rovirals with suicidality using FDA AERS data. 
Conference on Retroviruses and Opportunistic 
Infections (CROI), Seattle, WA.
NegreDo e., MaSSaNella M., PuertaS M.c., buzoN 
M.J., Puig J., et al. (2013). Early but limited ef-
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2014 325
fects of raltegravir intensification on CD4 T cell 
reconstitution in HIV-infected patients with an 
immunodiscordant response to antiretroviral 
therapy J. Antimicrob. Chemother. 68 (10), 2358-
2362.
NegreDo e., Miro o., roDriguez-SaNtiago b., garra-
bou g., eStaNy c., et al. (2009). Improvement of 
mitochondrial toxicity in patients receiving a nu-
cleoside reverse-transcriptase inhibitor-sparing 
strategy: results from the Multicenter Study with 
Nevirapine and Kaletra (MULTINEKA). Clin. In-
fect. Dis. 49, 892-900.
NelSoN M.r., elioN r.a., coheN c.J., MillS a., hoDDer 
S.l., et al. (2013). Rilpivirine versus efavirenz in 
HIV-1-infected subjects receiving emtricitabine/
tenofovir DF: pooled 96-week data from ECHO 
and THRIVE Studies. HIV Clin. Trials. 14, 81-91.
NiShiJiMa t., gataNaga h., ShiMbo t., koMatSu h., eNDo 
t., et al. (2013). Switching tenofovir/emtricit-
abine plus lopinavir/r to raltegravir plus Daruna-
vir/r in patients with suppressed viral load did 
not result in improvement of renal function but 
could sustain viral suppression: a randomized 
multicenter trial. PLoS One. 8, e73639.
NolaN S., wooD e. (2014). End of the debate about 
antiretroviral treatment initiation. Lancet Infect. 
Dis. 14, 258-259.
Nozza S., galli l., aNtiNori a., chiaPPetta S., Mazzot-
ta F., et al. (2014). Maraviroc 150 mg daily plus 
lopinavir/ritonavir, a nucleoside/nucleotide re-
verse transcriptase inhibitor-sparing regimen for 
HIV-infected naive patients: 48 week final results 
of VEMAN study. Clin. Microbiol. Infect.
oFotokuN i., ribauDo h., Na l., cohN S.e., goDFrey 
c., et al. (2014). Darunavir or atazanavir vs ral-
tegravir lipid changes are unlinked to ritonavir 
exposure: ACTG 5257. Conference on Retrovirus-
es and Opportunistic Infections (CROI), Boston, 
MA.
oFotokuN i., Sheth a.N., SaNForD S.e., eaSley k.a., 
SheNvi N., et al. (2012). A switch in therapy to 
a reverse transcriptase inhibitor sparing combi-
nation of lopinavir/ritonavir and raltegravir in 
virologically suppressed HIV-infected patients: a 
pilot randomized trial to assess efficacy and safe-
ty profile: the KITE study. AIDS Res. Hum. Retro-
viruses. 28, 1196-1206.
orkiN c., DeJeSuS e., khaNlou h., Stoehr a., SuPPa-
ratPiNyo k., et al. (2013). Final 192-week efficacy 
and safety of once-daily darunavir/ritonavir com-
pared with lopinavir/ritonavir in HIV-1-infected 
treatment-naive patients in the ARTEMIS trial. 
HIV Med. 14, 49-59.
ortiz r., DeJeSuS e., khaNlou h., voroNiN e., vaN 
luNzeN J., et al. (2008). Efficacy and safety of 
once-daily darunavir/ritonavir versus lopinavir/
ritonavir in treatment-naive HIV-1-infected pa-
tients at week 48. Aids. 22, 1389-1397.
oxeNiuS a., Price D.a., eaSterbrook P.J., o’callaghaN 
c.a., kelleher a.D., et al. (2000). Early highly 
active antiretroviral therapy for acute HIV-1 in-
fection preserves immune function of CD8+ and 
CD4+ T lymphocytes. Proc. Natl. Acad. Sci. USA. 
97, 3382-3387.
Palella F.J. Jr., FiSher M., teba P., gazzarD b., ruaNe 
P., et al. (2014). Simplification to rilpivirine/em-
tricitabine/tenofovir disoproxil fumarate from ri-
tonavir-boosted protease inhibitor antiretroviral 
therapy in a randomized trial of HIV-1 RNA-sup-
pressed participants. Aids. 28, 335-344.
Perez-MoliNa J.a., rubio r., rivero a., PaSquau J., 
Suárez i., et al. (2014). Switching to dual therapy 
(atazanavir/ritonavir + lamivudine) vs. standard 
triple therapy (atazanavir/ritonavir+2 nucleos[t]
ides) is safe and effective in virologically sup-
pressed patients: 48-week results of a random-
ized clinical trial (SALT study). 20th Internation-
al AIDS Conference, Melbourne, Australia.
PeterS M.g., aNDerSeN J, lyNch P., liu t., alStoN-
SMith b., et al. (2006). Randomized controlled 
study of tenofovir and adefovir in chronic hepati-
tis B virus and HIV infection: ACTG A5127. Hepa-
tology. 44, 1110-1116.
Pilcher c.D., tieN h.c., eroN J.J. Jr., verNazza P.l., 
leu S.y., et al. (2004). Brief but efficient: acute 
HIV infection and the sexual transmission of 
HIV. J. Infect. Dis. 189, 1785-1792.
PiNNetti c., loreNziNi P., cozzi-lePri a., SaNDriNe o., 
toMMaSi c., et al. (2014). Randomized trial of 
DRV/r or LPV/r QD monotherapy vs maintaining 
a PI/r-based antiretroviral regimen in persons 
with suppressed HIV replication. J. Int. AIDS 
Soc. 17 (Suppl. 3): 19809.
PletteNberg a, brockMeyer N.h., haaStert b., Mi-
chalik c., DuPke S., et al. (2011). Impact of ear-
lier HAART initiation on the immune status and 
clinical course of treated patients on the basis of 
cohort data of the German Competence Network 
for HIV/AIDS. Infection. 39, 3-12.
PoSt F.a., Moyle g.J., StellbriNk h.J., DoMiNgo P., 
PoDzaMczer D., et al. (2010). Randomized com-
parison of renal effects, efficacy, and safety with 
once-daily abacavir/lamivudine versus tenofovir/
emtricitabine, administered with efavirenz, in 
antiretroviral-naive, HIV-1-infected adults: 48-
week results from the ASSERT study. J. Acquir. 
Immune Defic. Syndr. 55, 49-57.
Potter M., oDueyuNgbo a., yaNg h., SaeeD S., kleiN 
M.b., et al. (2010). Impact of hepatitis C viral 
replication on CD4+ T-lymphocyte progression in 
HIV-HCV coinfection before and after antiretro-
viral therapy. Aids. 24, 1857-1865.
PozNiak a., Markowitz M., MillS a., StellbriNk h.J., 
aNtela a., et al. (2014). Switching to coformu-
lated elvitegravir, cobicistat, emtricitabine, and 
tenofovir versus continuation of non-nucleoside 
A. Antinori et al.326
reverse transcriptase inhibitor with emtricitabine 
and tenofovir in virologically suppressed adults 
with HIV (STRATEGY-NNRTI): 48 week results 
of a randomised, open-label, phase 3b non-inferi-
ority trial. Lancet Infect. Dis. 14, 590-599.
PuliDo F., Perez-valero i., DelgaDo r., arraNz a., 
PaSquau J., et al. (2009). Risk factors for loss 
of virological suppression in patients receiving 
lopinavir/ritonavir monotherapy for maintenance 
of HIV suppression. Antivir. Ther. 14, 195-201.
raFFi F., babiker a.g., richert l., MoliNa J.M., 
george e.c., et al. (2014). Ritonavir-boosted 
darunavir combined with raltegravir or tenofo-
vir-emtricitabine in antiretroviral-naive adults 
infected with HIV-1: 96 week results from the 
NEAT001/ANRS143 randomised non-inferiority 
trial. Lancet. 384, 1942-1951.
raFFi F., Jaeger h., quiroS-rolDaN e., albrecht h., 
beloNoSova e., et al. (2013a). Once-daily dolute-
gravir versus twice-daily raltegravir in antiretrovi-
ral-naive adults with HIV-1 infection (SPRING-2 
study): 96 week results from a randomised, dou-
ble-blind, non-inferiority trial. Lancet Infect. Dis. 
13, 927-935.
raFFi F., rachliS a., StellbriNk h.J., harDy w.D., 
torti c., et al. (2013b). Once-daily dolutegravir 
versus raltegravir in antiretroviral-naive adults 
with HIV-1 infection: 48 week results from 
the randomised, double-blind, non-inferiority 
SPRING-2 study. Lancet. 381, 735-743.
raiMoNDo M., caMoNi l., regiNe v., SalFa M.c., Dor-
rucci M., et al. (2013). Caratteristiche delle per-
sone che vivono con l’hiv e con l’AIDS in Italia. 
Not. Ist. Super. Sanità. 26, 3-6.
raPer J.l. (2014). Going the extra mile for retention 
and re-engagement in care: nurses make a differ-
ence. J. Assoc. Nurses AIDS Care. 25, 108-111.
reyNeS J., triNh r., PuliDo F., Soto-Malave r., gathe 
J., et al. (2013). Lopinavir/ritonavir combined 
with raltegravir or tenofovir/emtricitabine in an-
tiretroviral-naive subjects: 96 week results of the 
PROGRESS study. AIDS Res. Hum. Retroviruses. 
29, 256-265.
reyNolDS S.J., MakuMbi F., Nakigozi g., kagaayi J., 
gray r.h., et al. (2011). HIV-1 transmission 
among HIV-1 discordant couples before and after 
the introduction of antiretroviral therapy. Aids. 
25, 473-477.
riDDler S.a., haubrich r., Di rieNzo a.g., PeePleS l., 
PowDerly w.g., et al. (2008). Class-sparing regi-
mens for initial treatment of HIV-1 infection. N. 
Engl. J. Med. 358, 2095-2106.
robertSoN k.r., SMurzyNSki M., ParSoNS t.D., wu 
k., boSch r.J., et al. (2007). The prevalence and 
incidence of neurocognitive impairment in the 
HAART era. Aids. 21, 1915-1921.
rockStroh J.k., DeJeSuS e., leNNox J.l., yazDaNPaNah 
y., Saag M.S., et al. (2013). Durable efficacy 
and safety of raltegravir versus efavirenz when 
combined with tenofovir/emtricitabine in treat-
ment-naive HIV-1-infected patients: final 5-year 
results from STARTMRK. J. Acquir. Immune 
Defic. Syndr. 63, 77-85.
roSeNberg e.S., altFelD M., PooN S.h., PhilliPS 
M.N., wilkeS b.M., et al. (2000). Immune control 
of HIV-1 after early treatment of acute infection. 
Nature. 407, 523-526.
ryoM l., MocroFt a., kirk o., worM S.w., kaMara 
D.a., et al. (2013). Association between antiret-
roviral exposure and renal impairment among 
HIV-positive persons with normal baseline re-
nal function: the D:A:D study. J. Infect. Dis. 207, 
1359-1369.
Saez-cirioN a., bacchuS c., hocqueloux l., 
avettaND-FeNoel v., girault i., et al. (2013). 
Post-treatment HIV-1 controllers with a long-
term virological remission after the interruption 
of early initiated antiretroviral therapy ANRS 
Visconti Study. PLoS Pathog. 9, e1003211.
Sax P.e., DeJeSuS e., MillS a., zoloPa a., coheN c., et 
al. (2012). Co-formulated elvitegravir, cobicistat, 
emtricitabine, and tenofovir versus co-formulat-
ed efavirenz, emtricitabine, and tenofovir for ini-
tial treatment of HIV-1 infection: a randomised, 
double-blind, phase 3 trial, analysis of results af-
ter 48 weeks. Lancet. 379, 2439-2448.
Sax P.e., tierNey c., collier a.c., Daar e.S., Mol-
laN k., et al. (2011). Abacavir/lamivudine versus 
tenofovir DF/emtricitabine as part of combina-
tion regimens for initial treatment of HIV: final 
results. J. Infect. Dis. 204, 1191-1201.
Sax P.e., tierNey c., collier a.c., FiSchl M.a., Mol-
laN k., et al. (2009). Abacavir-lamivudine versus 
tenofovir-emtricitabine for initial HIV-1 therapy. 
N. Engl. J. Med. 361, 2230-2240.
Schacker t., collier a.c., hugheS J., Shea t., corey 
l. (1996). Clinical and epidemiologic features of 
primary HIV infection. Ann. Intern. Med. 125, 
257-264.
Scherzer r., eStrella M., li y., choi a.i., DeekS S.g., 
et al. (2012). Association of tenofovir exposure 
with kidney disease risk in HIV infection. Aids. 
26, 867-875.
Schwartz e.J., Szczech l.a., roSS M.J., klotMaN 
M.e., wiNStoN J.a., et al. (2005). Highly active 
antiretroviral therapy and the epidemic of HIV+ 
end-stage renal disease. J. Am. Soc. Nephrol. 16, 
2412-2420.
Severe P., JuSte M.a., aMbroiSe a., eliaciN l., March-
aND c., et al. (2010). Early versus standard an-
tiretroviral therapy for HIV-infected adults in 
Haiti. N. Engl. J. Med. 363, 257-265.
SibiuDe J., MaNDelbrot l., blaNche S., le cheNaDec 
J., boullag-boNNet N., et al. (2014). Association 
between prenatal exposure to antiretroviral ther-
apy and birth defects: an analysis of the French 
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2014 327
perinatal cohort study (ANRS CO1/CO11). PLoS 
Med. 11, e1001635.
SMith k.y., Patel P., FiNe D., belloS N., SloaN l., 
et al. (2009). Randomized, double-blind, place-
bo-matched, multicenter trial of abacavir/lami-
vudine or tenofovir/emtricitabine with lopina-
vir/ritonavir for initial HIV treatment. Aids. 23, 
1547-1556.
SoriaNo v., araSteh k., MigroNe h., lutz t., oPravil 
M., et al. (2011). Nevirapine versus atazanavir/ri-
tonavir, each combined with tenofovir disoproxil 
fumarate/emtricitabine, in antiretroviral-naive 
HIV-1 patients: the ARTEN Trial. Antivir. Ther. 
16, 339-348.
SPagNuolo v., galli l., bigoloNi a., Nozza S., MoN-
Forte a., et al. (2014). Atazanavir/ritonavir mono-
therapy as maintenance strategy in HIV-1 treated 
subjects with viral suppression: 96-week analysis 
results of the MODAT study. J. Int. AIDS Soc. 17, 
(Suppl. 3): 19806.
StellbriNk h.J., orkiN c., arribaS J.r., coMPStoN J., 
gerStoFt J., et al. (2010). Comparison of changes 
in bone density and turnover with abacavir-lami-
vudine versus tenofovir-emtricitabine in HIV-in-
fected adults: 48-week results from the ASSERT 
study. Clin. Infect. Dis. 51, 963-972.
StrategieS For MaNageMeNt oF aNtiretroviral thera-
Py StuDy, g, eMery S., NeuhauS J.a., PhilliPS a.N., 
babiker a., et al. (2008). Major clinical outcomes 
in antiretroviral therapy (ART)-naive participants 
and in those not receiving ART at baseline in the 
SMART study. J. Infect. Dis. 197, 1133-1144.
Stricker S.M., Fox k.a., baggaley r., NeguSSie e., De 
Pee S., et al. (2014). Retention in care and adher-
ence to ART are critical elements of HIV care in-
terventions. AIDS Behav. 18 (Suppl. 5): S465-475.
SwiNDellS S., Di rieNzo a.g., wilkiN t., Fletcher c.v., 
MargoliS D.M., et al. (2006). Regimen simplifica-
tion to atazanavir-ritonavir alone as maintenance 
antiretroviral therapy after sustained virologic 
suppression. JAMA. 296, 806-814.
thio c.l., Seaberg e.c., SkolaSky r. Jr., Phair J., 
viSScher b., et al. (2002). HIV-1, hepatitis B vi-
rus, and risk of liver-related mortality in the 
Multicenter Cohort Study (MACS). Lancet. 360, 
1921-1926.
thoMPSoN M.a., Mugavero M.J., aMico k.r., cargill 
v.a., chaNg l.w., et al. (2012). Guidelines for 
improving entry into and retention in care and 
antiretroviral adherence for persons with HIV: 
evidence-based recommendations from an Inter-
national Association of Physicians in AIDS Care 
panel. Ann. Intern. Med. 156, 817-833, W-284-
294.
tubiaNa r., le cheNaDec J., rouzioux c., MaNDelbrot 
l., haMreNe k., et al. (2010). Factors associated 
with mother-to-child transmission of HIV-1 de-
spite a maternal viral load <500 copies/ml at de-
livery: a case-control study nested in the French 
perinatal cohort (EPF-ANRS CO1). Clin. Infect. 
Dis. 50, 585-596.
valaNtiN M.a., laMbert-Niclot S., FlaNDre P., Mo-
raND-Joubert l., cabie a., et al. (2012). Long-term 
efficacy of darunavir/ritonavir monotherapy in 
patients with HIV-1 viral suppression: week 96 
results from the MONOI ANRS 136 study. J. Anti-
microb. Chemother. 67, 691-695.
vaN leth F., PhaNuPhak P., ruxruNgthaM k., baralDi 
e., Miller S., et al. (2004). Comparison of first-
line antiretroviral therapy with regimens includ-
ing nevirapine, efavirenz, or both drugs, plus 
stavudine and lamivudine: a randomised open-la-
bel trial, the 2NN Study. Lancet. 363, 1253-1263.
vaN luNzeN J., PozNiak a., gatell J., aNtiNori a., 
klauck i., et al. (2014). HARNESS study: ri-
tonavir-boosted atazanavir (ATV/r)+raltegravir 
(RAL) switch study in virologically suppressed, 
HIV-1-infected patients. International AIDS Con-
ference, Melbourne, Australia.
walMSley S.l., aNtela a., cluMeck N., DuiculeScu 
D., eberharD a., et al. (2013). Dolutegravir plus 
abacavir-lamivudine for the treatment of HIV-1 
infection. N. Engl. J. Med. 369, 1807-1818.
wheN to Start c., SterNe J.a., May M., coStagliola 
D., De wolF F., et al. (2009). Timing of initiation 
of antiretroviral therapy in AIDS-free HIV-1-in-
fected patients: a collaborative analysis of 18 HIV 
cohort studies. Lancet. 373, 1352-1363.
wohl D.a., coheN c., gallaNt J.e., MillS a., Sax 
P.e., et al. (2014). A randomized, double-blind 
comparison of single-tablet regimen elvitegravir/
cobicistat/emtricitabine/tenofovir DF versus sin-
gle-tablet regimen efavirenz/emtricitabine/teno-
fovir DF for initial treatment of HIV-1 infection: 
analysis of week 144 results. J. Acquir. Immune 
Defic. Syndr. 65, e118-120.
woNg k.h., chaN k.c., cheNg k.l., chaN w.k., kaM 
k.M., et al. (2007). Establishing CD4 thresholds 
for highly active antiretroviral therapy initiation 
in a cohort of HIV-infected adult Chinese in Hong 
Kong. AIDS Patient Care STDS. 21, 106-115.
yehia b.r., FreNch b., FleiShMaN J.a., Metlay J.P., 
berry S.a., et al. (2014). Retention in care is 
more strongly associated with viral suppression 
in HIV-infected patients with lower versus higher 
CD4 counts. J. Acquir. Immune Defic. Syndr. 65, 
333-339.
youNg J., SchaFer J., Fux c.a., Furrer h., berNaScoNi 
e., et al. (2012). Renal function in patients with 
HIV starting therapy with tenofovir and either 
efavirenz, lopinavir or atazanavir. Aids. 26, 567-
575.
BIANCA
